

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 April 2003 (10.04.2003)

PCT

(10) International Publication Number
WO 03/029459 A2

(51) International Patent Classification⁷: **C12N 15/11**,
A61K 48/00

37083 Göttingen (DE). **RAUHUT, Reinhard** [DE/DE];
Merkelstrasse 16, 37085 Göttingen (DE).

(21) International Application Number: PCT/EP02/10881

(74) Agents: **WEICKMANN, Franz, Albert** et al.; Weick-
mann & Weickmann, Postfach 860 820, 81635 München
(DE).

(22) International Filing Date:

27 September 2002 (27.09.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

01123453.1 28 September 2001 (28.09.2001) EP
02006712.0 22 March 2002 (22.03.2002) EP
02016772.2 26 July 2002 (26.07.2002) EP

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **MAX-
PLANCK-GESELLSCHAFT ZUR FÖRDERUNG
DER WISSENSCHAFTEN E.V.** [DE/DE]; Hofgarten-
strasse 8, 80539 München (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **TUSCHL, Thomas**
[DE/DE]; Keplerstrasse 9, 37085 Göttingen (DE). **LAGOS-QUINTANA, Mariana** [MX/DE]; Kurze Geis-
marstrasse 13, 37073 Göttingen (DE). **LENDECKEL,
Winfried** [DE/DE]; Blinde Gasse 52, 37318 Hohengand-
ern (DE). **MEYER, Jutta** [DE/DE]; Sternstrasse 16,

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: MICRORNA MOLECULES

(57) Abstract: In *Caenorhabditis elegans*, *lin-4* and *let-7* encode 22- and 21 -nucleotide RNAs, respectively, that function as key regulators of developmental timing. Because the appearance of these short RNAs is regulated during development, they are also referred to as "small temporal RNAs" (stRNAs). We show that many more 21- and 22-nt expressed RNAs, termed microRNAs, (miRNAs), exist in invertebrates and vertebrates, and that some of these novel RNAs, similar to *let-7* stRNA, are also highly conserved. This suggests that sequence-specific post-transcriptional regulatory mechanisms mediated by small RNAs are more general than previously appreciated.



WO 03/029459 A2

- 1 -

MicroRNA molecules**Description**

5

The present invention relates to novel small expressed (micro)RNA molecules associated with physiological regulatory mechanisms, particularly in developmental control.

10 In *Caenorhabditis elegans*, *lin-4* and *let-7* encode 22- and 21-nucleotide RNAs, respectively (1, 2), that function as key regulators of developmental timing (3-5). Because the appearance of these short RNAs is regulated during development, they are also referred to as "microRNAs" (miRNAs) or small temporal RNAs (stRNAs) (6). *lin-4* and *let-21* are the only known
15 miRNAs to date.

Two distinct pathways exist in animals and plants in which 21- to 23-nucleotide RNAs function as post-transcriptional regulators of gene expression. Small interfering RNAs (siRNAs) act as mediators of sequence-specific mRNA degradation in RNA interference (RNAi) (7-11) whereas
20 miRNAs regulate developmental timing by mediating sequence-specific repression of mRNA translation (3-5). siRNAs and miRNAs are excised from double-stranded RNA (dsRNA) precursors by Dicer (12, 13, 29), a multidomain RNase III protein, thus producing RNA species of similar size.
25 However, siRNAs are believed to be double-stranded (8, 11, 12), while miRNAs are single-stranded (6).

We show that many more short, particularly 21- and 22-nt expressed RNAs, termed microRNAs (miRNAs), exist in invertebrates and vertebrates,
30 and that some of these novel RNAs, similar to *let-7* RNA (6), are also highly conserved. This suggests that sequence-specific post-transcriptional

- 2 -

regulatory mechanisms mediated by small RNAs are more general than previously appreciated.

The present invention relates to an isolated nucleic acid molecule comprising:

(a) a nucleotide sequence as shown in Table 1, Table 2, Table 3 or Table 4

(b) a nucleotide sequence which is the complement of (a),

(c) a nucleotide sequence which has an identity of at least 80%, preferably of at least 90% and more preferably of at least 99%, to a sequence of (a) or (b) and/or

(d) a nucleotide sequence which hybridizes under stringent conditions to a sequence of (a), (b) and/or (c).

In a preferred embodiment the invention relates to miRNA molecules and analogs thereof, to miRNA precursor molecules and to DNA molecules encoding miRNA or miRNA precursor molecules.

Preferably the identity of sequence (c) to a sequence of (a) or (b) is at least 90%, more preferably at least 95%. The determination of identity (percent) may be carried out as follows:

$$I = n : L$$

wherein I is the identity in percent, n is the number of identical nucleotides between a given sequence and a comparative sequence as shown in Table 1, Table 2, Table 3 or Table 4 and L is the length of the comparative sequence. It should be noted that the nucleotides A, C, G and U as depicted in Tables 1, 2, 3 and 4 may denote ribonucleotides,

- 3 -

deoxyribonucleotides and/or other nucleotide analogs, e.g. synthetic non-naturally occurring nucleotide analogs. Further nucleobases may be substituted by corresponding nucleobases capable of forming analogous H-bonds to a complementary nucleic acid sequence, e.g. U may be substituted by T.

Further, the invention encompasses nucleotide sequences which hybridize under stringent conditions with the nucleotide sequence as shown in Table 1, Table 2, Table 3 or Table 4, a complementary sequence thereof or a highly identical sequence. Stringent hybridization conditions comprise washing for 1 h in 1 x SSC and 0.1% SDS at 45°C, preferably at 48°C and more preferably at 50°C, particularly for 1 h in 0.2 x SSC and 0.1% SDS.

The isolated nucleic acid molecules of the invention preferably have a length of from 18 to 100 nucleotides, and more preferably from 18 to 80 nucleotides. It should be noted that mature miRNAs usually have a length of 19-24 nucleotides, particularly 21, 22 or 23 nucleotides. The miRNAs, however, may be also provided as a precursor which usually has a length of 50-90 nucleotides, particularly 60-80 nucleotides. It should be noted that the precursor may be produced by processing of a primary transcript which may have a length of >100 nucleotides.

The nucleic acid molecules may be present in single-stranded or double-stranded form. The miRNA as such is usually a single-stranded molecule, while the mi-precursor is usually an at least partially self-complementary molecule capable of forming double-stranded portions, e.g. stem- and loop-structures. DNA molecules encoding the miRNA and miRNA precursor molecules. The nucleic acids may be selected from RNA, DNA or nucleic acid analog molecules, such as sugar- or backbone-modified ribonucleotides or deoxyribonucleotides. It should be noted, however, that other nucleic analogs, such as peptide nucleic acids (PNA) or locked nucleic acids (LNA), are also suitable.

- 4 -

In an embodiment of the invention the nucleic acid molecule is an RNA- or DNA molecule, which contains at least one modified nucleotide analog, i.e. a naturally occurring ribonucleotide or deoxyribonucleotide is substituted by a non-naturally occurring nucleotide. The modified nucleotide analog
5 may be located for example at the 5'-end and/or the 3'-end of the nucleic acid molecule.

Preferred nucleotide analogs are selected from sugar- or backbone-modified ribonucleotides. It should be noted, however, that also nucleobase-
10 modified ribonucleotides, i.e. ribonucleotides, containing a non-naturally occurring nucleobase instead of a naturally occurring nucleobase such as uridines or cytidines modified at the 5-position, e.g. 5-(2-amino)propyl uridine, 5-bromo uridine; adenosines and guanosines modified at the 8-
position, e.g. 8-bromo guanosine; deaza nucleotides, e.g. 7-deaza-
15 adenosine; O- and N-alkylated nucleotides, e.g. N6-methyl adenosine are suitable. In preferred sugar-modified ribonucleotides the 2'-OH-group is replaced by a group selected from H, OR, R, halo, SH, SR, NH₂, NHR, NR₂ or CN, wherein R is C₁-C₆ alkyl, alkenyl or alkynyl and halo is F, Cl, Br or I. In preferred backbone-modified ribonucleotides the phosphoester group
20 connecting to adjacent ribonucleotides is replaced by a modified group, e.g. of phosphothioate group. It should be noted that the above modifications may be combined.

The nucleic acid molecules of the invention may be obtained by chemical
25 synthesis methods or by recombinant methods, e.g. by enzymatic transcription from synthetic DNA-templates or from DNA-plasmids isolated from recombinant organisms. Typically phage RNA-polymerases are used for transcription, such as T7, T3 or SP6 RNA-polymerases.

30 The invention also relates to a recombinant expression vector comprising a recombinant nucleic acid operatively linked to an expression control sequence, wherein expression, i.e. transcription and optionally further

- 5 -

processing results in a miRNA-molecule or miRNA precursor molecule as described above. The vector is preferably a DNA-vector, e.g. a viral vector or a plasmid, particularly an expression vector suitable for nucleic acid expression in eukaryotic, more particularly mammalian cells. The
5 recombinant nucleic acid contained in said vector may be a sequence which results in the transcription of the miRNA-molecule as such, a precursor or a primary transcript thereof, which may be further processed to give the miRNA-molecule.

10 Further, the invention relates to diagnostic or therapeutic applications of the claimed nucleic acid molecules. For example, miRNAs may be detected in biological samples, e.g. in tissue sections, in order to determine and classify certain cell types or tissue types or miRNA-associated pathogenic disorders which are characterized by differential expression of miRNA-
15 molecules or miRNA-molecule patterns. Further, the developmental stage of cells may be classified by determining temporarily expressed miRNA-molecules.

Further, the claimed nucleic acid molecules are suitable for therapeutic
20 applications. For example, the nucleic acid molecules may be used as modulators or targets of developmental processes or disorders associated with developmental dysfunctions, such as cancer. For example, miR-15 and miR-16 probably function as tumor-suppressors and thus expression or delivery of these RNAs or analogs or precursors thereof to tumor cells may
25 provide therapeutic efficacy, particularly against leukemias, such as B-cell chronic lymphocytic leukemia (B-CLL). Further, miR-10 is a possible regulator of the translation of Hox Genes, particularly Hox 3 and Hox 4 (or Scr and Dfd in *Drosophila*).

30 In general, the claimed nucleic acid molecules may be used as a modulator of the expression of genes which are at least partially complementary to said nucleic acid. Further, miRNA molecules may act as target for

- 6 -

therapeutic screening procedures, e.g. inhibition or activation of miRNA molecules might modulate a cellular differentiation process, e.g. apoptosis.

Furthermore, existing miRNA molecules may be used as starting materials
5 for the manufacture of sequence-modified miRNA molecules, in order to modify the target-specificity thereof, e.g. an oncogene, a multidrug-resistance gene or another therapeutic target gene. The novel engineered miRNA molecules preferably have an identity of at least 80% to the starting miRNA, e.g. as depicted in Tables 1, 2, 3 and 4. Further, miRNA
10 molecules can be modified, in order that they are symetrically processed and then generated as double-stranded siRNAs which are again directed against therapeutically relevant targets.

Furthermore, miRNA molecules may be used for tissue reprogramming
15 procedures, e.g. a differentiated cell line might be transformed by expression of miRNA molecules into a different cell type or a stem cell.

For diagnostic or therapeutic applications, the claimed RNA molecules are preferably provided as a pharmaceutical composition. This pharmaceutical
20 composition comprises as an active agent at least one nucleic acid molecule as described above and optionally a pharmaceutically acceptable carrier.

The administration of the pharmaceutical composition may be carried out
25 by known methods, wherein a nucleic acid is introduced into a desired target cell in vitro or in vivo.

Commonly used gene transfer techniques include calcium phosphate, DEAE-dextran, electroporation and microinjection and viral methods [30,
30 31, 32, 33, 34]. A recent addition to this arsenal of techniques for the introduction of DNA into cells is the use of cationic liposomes [35].

- 7 -

Commercially available cationic lipid formulations are e.g. Tfx 50 (Promega) or Lipofectamin 2000 (Life Technologies).

5 The composition may be in form of a solution, e.g. an injectable solution, a cream, ointment, tablet, suspension or the like. The composition may be administered in any suitable way, e.g. by injection, by oral, topical, nasal, rectal application etc. The carrier may be any suitable pharmaceutical carrier. Preferably, a carrier is used, which is capable of increasing the efficacy of the RNA molecules to enter the target-cells. Suitable examples
10 of such carriers are liposomes, particularly cationic liposomes.

Further, the invention relates to a method of identifying novel microRNA-molecules and precursors thereof, in eukaryotes, particularly in vertebrates and more particularly in mammals, such as humans or mice. This method
15 comprises: ligating 5'- and 3'-adapter-molecules to the end of a size-fractionated RNA-population, reverse transcribing said adapter-ligated RNA-population, and characterizing said reverse transcribed RNA-molecules, e.g. by amplification, concatamerization, cloning and sequencing.

20 A method as described above already has been described in (8), however, for the identification of siRNA molecules. Surprisingly, it was found now that the method is also suitable for identifying the miRNA molecules or precursors thereof as claimed in the present application.

25 Further, it should be noted that as 3'-adaptor for derivatization of the 3'-OH group not only 4-hydroxymethylbenzyl but other types of derivatization groups, such as alkyl, alkyl amino, ethylene glycol or 3'-deoxy groups are suitable.

30 Further, the invention shall be explained in more detail by the following Figures and Examples:

- 8 -

Figure Legends

Fig. 1A. Expression of *D. melanogaster* miRNAs. Northern blots of total RNA isolated from staged populations of *D. melanogaster* were probed for the indicated miRNAs. The position of 76-nt val-tRNA is also indicated on the blots. 5S rRNA serves as loading control. E, embryo; L, larval stage; P, pupae; A, adult; S2, Schneider-2 cells. It should be pointed out, that S2 cells are polyclonal, derived from an unknown subset of embryonic tissues, and may have also lost some features of their tissue of origin while maintained in culture. miR-3 to miR-6 RNAs were not detectable in S2 cells (data not shown). miR-14 was not detected by Northern blotting and may be very weakly expressed, which is consistent with its cloning frequency. Similar miRNA sequences are difficult to distinguish by Northern blotting because of potential cross-hybridization of probes.

Fig. 1B. Expression of vertebrate miRNAs. Northern blots of total RNA isolated from HeLa cells, mouse kidneys, adult zebrafish, frog ovaries, and S2 cells were probed for the indicated miRNAs. The position of 76-nt val-tRNA is also indicated on the blots. 5S rRNA from the preparations of total RNA from the indicated species is also shown. The gels used for probing of miR-18, miR-19a, miR-30, and miR-31 were not run as far as the other gels (see tRNA marker position). miR-32 and miR-33 were not detected by Northern blotting, which is consistent with their low cloning frequency. Oligodeoxynucleotides used as Northern probes were:

let-7a, 5' TACTATACAACCTACTACCTCAATTTGCC (SEQ ID NO:1);
 let-7d, 5' ACTATGCAACCTACTACCTCT (SEQ ID NO:2);
 let-7e, 5' ACTATACAACCTCCTACCTCA (SEQ ID NO:3);
D. melanogaster val-tRNA, 5' TGGTGTTCGCCCCGGGAA (SEQ ID NO:4);
 miR-1, 5' TGGAATGTAAAGAAGTATGGAG (SEQ ID NO:5);
 miR-2b, 5' GCTCCTCAAAGCTGGCTGTGATA (SEQ ID NO:6);
 miR-3, 5' TGAGACACACTTTGCCAGTGA (SEQ ID NO:7);
 miR-4, 5' TCAATGGTTGTCTAGCTTTAT (SEQ ID NO:8);

- 9 -

miR-5, 5' CATATCACAACGATCGTTCCTTT (SEQ ID NO:9);
 miR-6, 5' AAAAAGAACAGCCACTGTGATA (SEQ ID NO:10);
 miR-7, 5' TGGAAGACTAGTGATTTTGTGT (SEQ ID NO:11);
 miR-8, 5' GACATCTTTACCTGACAGTATTA (SEQ ID NO:12);
 5 miR-9, 5' TCATACAGCTAGATAACCAAAGA (SEQ ID NO:13);
 miR-10, 5' ACAAATTCGGATCTACAGGGT (SEQ ID NO:14);
 miR-11, 5' GCAAGAACTCAGACTGTGATG (SEQ ID NO:15);
 miR-12, 5' ACCAGTACCTGATGTAATACTCA (SEQ ID NO:16);
 miR-13a, 5' ACTCGTCAAAATGGCTGTGATA (SEQ ID NO:17);
 10 miR-14, 5' TAGGAGAGAGAAAAAGACTGA (SEQ ID NO:18);
 miR-15, 5' TAGCAGCACATAATGGTTTGT (SEQ ID NO:19);
 miR-16, 5' GCCAATATTTACGTGCTGCTA (SEQ ID NO:20);
 miR-17, 5' TACAAGTGCCTTCACTGCAGTA (SEQ ID NO:21);
 miR-18, 5' TATCTGCACTAGATGCACCTTA (SEQ ID NO:22);
 15 miR-19a, 5' TCAGTTTTGCATAGATTTGCACA (SEQ ID NO:23);
 miR-20, 5' TACCTGCACTATAAGCACTTTA (SEQ ID NO:24);
 miR-21, 5' TCAACATCAGTCTGATAAGCTA (SEQ ID NO:25);
 miR-22, 5' ACAGTTCTTCAACTGGCAGCTT (SEQ ID NO:26);
 miR-23, 5' GGAAATCCCTGGCAATGTGAT (SEQ ID NO:27);
 20 miR-24, 5' CTGTTCTGCTGAACTGAGCCA (SEQ ID NO:28);
 miR-25, 5' TCAGACCGAGACAAGTGCAATG (SEQ ID NO:29);
 miR-26a, 5' AGCCTATCCTGGATTACTTGAA (SEQ ID NO:30);
 miR-27, 5' AGCGGAAGTTAGCCACTGTGAA (SEQ ID NO:31);
 miR-28, 5' CTCAATAGACTGTGAGCTCCTT (SEQ ID NO:32);
 25 miR-29, 5' AACCGATTTTCAGATGGTGCTAG (SEQ ID NO:33);
 miR-30, 5' GCTGCAAACATCCGACTGAAAG (SEQ ID NO:34);
 miR-31, 5' CAGCTATGCCAGCATCTTGCCT (SEQ ID NO:35);
 miR-32, 5' GCAACTTAGTAATGTGCAATA (SEQ ID NO:36);
 miR-33, 5' TGCAATGCAACTACAATGCACC (SEQ ID NO:37).

30

Fig. 2. Genomic organization of miRNA gene clusters. The precursor structure is indicated as box and the location of the miRNA within the

- 10 -

precursor is shown in gray; the chromosomal location is also indicated to the right. (A) *D. melanogaster* miRNA gene clusters. (B) Human miRNA gene clusters. The cluster of let-7a-1 and let-7f-1 is separated by 26500 nt from a copy of let-7d on chromosome 9 and 17. A cluster of let-7a-3 and let-7b, separated by 938 nt on chromosome 22, is not illustrated.

Fig. 3. Predicted precursor structures of *D. melanogaster* miRNAs. RNA secondary structure prediction was performed using mfold version 3.1 [28] and manually refined to accommodate G/U wobble base pairs in the helical segments. The miRNA sequence is underlined. The actual size of the stem-loop structure is not known experimentally and may be slightly shorter or longer than represented. Multicopy miRNAs and their corresponding precursor structures are also shown.

Fig. 4. Predicted precursor structures of human miRNAs. For legend, see Fig. 3.

Fig. 5. Expression of novel mouse miRNAs. Northern blot analysis of novel mouse miRNAs. Total RNA from different mouse tissues was blotted and probed with a 5'-radiolabeled oligodeoxynucleotide complementary to the indicated miRNA. Equal loading of total RNA on the gel was verified by ethidium bromide staining prior to transfer; the band representing tRNAs is shown. The fold-back precursors are indicated with capital L. Mouse brains were dissected into midbrain, mb, cortex, cx, cerebellum, cb. The rest of the brain, rb, was also used. Other tissues were heart, ht, lung, lg, liver, lv, colon, co, small intestine, si, pancreas, pc, spleen, sp, kidney, kd, skeletal muscle, sm, stomach, st, H, human Hela SS3 cells. Oligodeoxynucleotides used as Northern probes were:

miR-1a, CTCCATACTTCTTTACATTCCA (SEQ ID NO:38);
 miR-30b, GCTGAGTGTAGGATGTTTACA (SEQ ID NO:39);
 miR-30a-s, GCTTCCAGTCGAGGATGTTTACA (SEQ ID NO:40);
 miR-99b, CGCAAGGTCGGTTCTACGGGTG (SEQ ID NO:41);

- 11 -

miR-101, TCAGTTATCACAGTACTGTA (SEQ ID NO:42);
 miR-122a, ACAAACACCATTGTCACTCCA (SEQ ID NO:43);
 miR-124a, TGGCATTACCGCGTGCCTTA (SEQ ID NO:44);
 miR-125a, CACAGGTTAAAGGGTCTCAGGGA (SEQ ID NO:45);
 5 miR-125b, TCACAAGTTAGGGTCTCAGGGA (SEQ ID NO:46);
 miR-127, AGCCAAGCTCAGACGGATCCGA (SEQ ID NO:47);
 miR-128, AAAAGAGACCGGTTCACTCTGA (SEQ ID NO:48);
 miR-129, GCAAGCCCAGACCGAAAAAAG (SEQ ID NO:49);
 miR-130, GCCCTTTTAACATTGCACTC (SEQ ID NO:50);
 10 miR-131, ACTTTCGGTTATCTAGCTTTA (SEQ ID NO:51);
 miR-132, ACGACCATGGCTGTAGACTGTTA (SEQ ID NO:52);
 miR-143, TGAGCTACAGTGCTTCATCTCA (SEQ ID NO:53).

15 Fig.6. Potential orthologs of lin-4 stRNA. (A) Sequence alignment of *C. elegans* lin-4 stRNA with mouse miR-125a and miR-125b and the *D. melanogaster* miR-125. Differences are highlighted by gray boxes. (B) Northern blot of total RNA isolated from staged populations of *D. melanogaster*, probed for miR-125. E, embryo; L, larval stage; P, pupae; A,
 20 adult; S2, Schneider-2 cells.

Fig. 7. Predicted precursor structures of miRNAs, sequence accession numbers and homology information. RNA secondary structure prediction was performed using mfold version 3.1 and manually refined to
 25 accommodate G/U wobble base pairs in the helical segments. Dashes were inserted into the secondary structure presentation when asymmetrically bulged nucleotides had to be accommodated. The excised miRNA sequence is underlined. The actual size of the stem-loop structure is not known experimentally and may be slightly shorter or longer than
 30 represented. Multicopy miRNAs and their corresponding precursor structures are also shown. In cases where no mouse precursors were yet deposited in the database, the human orthologs are indicated. miRNAs

- 12 -

which correspond to *D. melanogaster* or human sequences are included. Published *C. elegans* miRNAs [36, 37] are also included in the table. A recent set of new HeLa cell miRNAs is also indicated [46]. If several ESTs were retrieved for one organism in the database, only those with different precursor sequences are listed. miRNA homologs found in other species are indicated. Chromosomal location and sequence accession numbers, and clusters of miRNA genes are indicated. Sequences from cloned miRNAs were searched against mouse and human in GenBank (including trace data), and against *Fugu rubripes* and *Danio rerio* at www.jgi.doe.gov and www.sanger.ac.uk, respectively.

EXAMPLE 1: MicroRNAs from *D. melanogaster* and human.

We previously developed a directional cloning procedure to isolate siRNAs after processing of long dsRNAs in *Drosophila melanogaster* embryo lysate (8). Briefly, 5' and 3' adapter molecules were ligated to the ends of a size-fractionated RNA population, followed by reverse transcription, PCR amplification, concatamerization, cloning and sequencing. This method, originally intended to isolate siRNAs, led to the simultaneous identification of 14 novel 20- to 23-nt short RNAs which are encoded in the *D. melanogaster* genome and which are expressed in 0 to 2 h embryos (Table 1). The method was adapted to clone RNAs in a similar size range from HeLa cell total RNA (14), which led to the identification of 19 novel human stRNAs (Table 2), thus providing further evidence for the existence of a large class of small RNAs with potential regulatory roles. According to their small size, we refer to these novel RNAs as microRNAs or miRNAs. The miRNAs are abbreviated as miR-1 to miR-33, and the genes encoding miRNAs are named mir-1 to mir-33. Highly homologous miRNAs are classified by adding a lowercase letter, followed by a dash and a number for designating multiple genomic copies of a mir gene.

- 13 -

The expression and size of the cloned, endogenous short RNAs was also examined by Northern blotting (Fig. 1, Table 1 and 2). Total RNA isolation was performed by acid guanidinium thiocyanate-phenol-chloroform extraction [45]. Northern analysis was performed as described [1], except
5 that the total RNA was resolved on a 15% denaturing polyacrylamide gel, transferred onto Hybond-N+ membrane (Amersham Pharmacia Biotech), and the hybridization and wash steps were performed at 50°C. Oligodeoxynucleotides used as Northern probes were 5'-32P-phosphorylated, complementary to the miRNA sequence and 20 to 25 nt in
10 length.

5S rRNA was detected by ethidium staining of polyacrylamide gels prior to transfer. Blots were stripped by boiling in 0.1% aqueous sodium dodecylsulfate/0.1x SSC (15 mM sodium chloride, 1.5 mM sodium citrate,
15 pH 7.0) for 10 min, and were re-probed up to 4 times until the 21-nt signals became too weak for detection. Finally, blots were probed for val-tRNA as size marker.

For analysis of *D. melanogaster* RNAs, total RNA was prepared from
20 different developmental stages, as well as cultured Schneider-2 (S2) cells, which originally derive from 20-24 h *D. melanogaster* embryos [15] (Fig. 1, Table 1). miR-3 to miR-7 are expressed only during embryogenesis and not at later developmental stages. The temporal expression of miR-1, miR-2 and miR-8 to miR-13 was less restricted. These miRNAs were observed at
25 all developmental stages though significant variations in the expression levels were sometimes observed. Interestingly, miR-1, miR-3 to miR-6, and miR-8 to miR-11 were completely absent from cultured Schneider-2 (S2) cells, which were originally derived from 20-24 h *D. melanogaster* embryos [15], while miR-2, miR-7, miR-12, and miR-13 were present in S2 cells,
30 therefore indicating cell type-specific miRNA expression. miR-1, miR-8, and miR-12 expression patterns are similar to those of lin-4 stRNA in *C. elegans*, as their expression is strongly upregulated in larvae and sustained

- 14 -

to adulthood [16]. miR-9 and miR-11 are present at all stages but are strongly reduced in the adult which may reflect a maternal contribution from germ cells or expression in one sex only.

5 The mir-3 to mir-6 genes are clustered (Fig. 2A), and mir-6 is present as triple repeat with slight variations in the mir-6 precursor sequence but not in the miRNA sequence itself. The expression profiles of miR-3 to miR-6 are highly similar (Table 1), which suggests that a single embryo-specific precursor transcript may give rise to the different miRNAs, or that the
10 same enhancer regulates miRNA-specific promoters. Several other fly miRNAs are also found in gene clusters (Fig. 2A).

The expression of HeLa cell miR-15 to miR-33 was examined by Northern blotting using HeLa cell total RNA, in addition to total RNA prepared from
15 mouse kidneys, adult zebrafish, *Xenopus laevis* ovary, and *D. melanogaster* S2 cells (Fig. 1B, Table 2). miR-15 and miR-16 are encoded in a gene cluster (Fig. 2B) and are detected in mouse kidney, fish, and very weakly in frog ovary, which may result from miRNA expression in somatic ovary tissue rather than oocytes. mir-17 to mir-20 are also clustered (Fig. 2B),
20 and are expressed in HeLa cells and fish, but undetectable in mouse kidney and frog ovary (Fig. 1, Table 2), and therefore represent a likely case of tissue-specific miRNA expression.

The majority of vertebrate and invertebrate miRNAs identified in this study
25 are not related by sequence, but a few exceptions, similar to the highly conserved let-7 RNA [6], do exist. Sequence analysis of the *D. melanogaster* miRNAs revealed four such examples of sequence conservation between invertebrates and vertebrates. miR-1 homologs are encoded in the genomes of *C. elegans*, *C. briggsae*, and humans, and are
30 found in cDNAs from zebrafish, mouse, cow and human. The expression of mir-1 was detected by Northern blotting in total RNA from adult zebrafish and *C. elegans*, but not in total RNA from HeLa cells or mouse kidney

- 15 -

(Table 2 and data not shown). Interestingly, while mir-1 and let-7 are expressed both in adult flies (Fig. 1A) [6] and are both undetected in S2 cells, miR-1 is, in contrast to let-7, undetectable in HeLa cells. This represents another case of tissue-specific expression of a miRNA, and indicates that miRNAs may not only play a regulatory role in developmental timing, but also in tissue specification. miR-7 homologs were found by database searches in mouse and human genomic and expressed sequence tag sequences (ESTs). Two mammalian miR-7 variants are predicted by sequence analysis in mouse and human, and were detected by Northern blotting in HeLa cells and fish, but not in mouse kidney (Table 2). Similarly, we identified mouse and human miR-9 and miR-10 homologs by database searches but only detected mir-10 expression in mouse kidney.

The identification of evolutionary related miRNAs, which have already acquired multiple sequence mutations, was not possible by standard bioinformatic searches. Direct comparison of the *D. melanogaster* miRNAs with the human miRNAs identified an 11-nt segment shared between *D. melanogaster* miR-6 and HeLa miR-27, but no further relationships were detected. One may speculate that most miRNAs only act on a single target and therefore allow for rapid evolution by covariation, and that highly conserved miRNAs act on more than one target sequence, and therefore have a reduced probability for evolutionary drift by covariation [6]. An alternative interpretation is that the sets of miRNAs from *D. melanogaster* and humans are fairly incomplete and that many more miRNAs remain to be discovered, which will provide the missing evolutionary links.

lin-4 and let-7 stRNAs were predicted to be excised from longer transcripts that contain approximately 30 base-pair stem-loop structures [1, 6]. Database searches for newly identified miRNAs revealed that all miRNAs are flanked by sequences that have the potential to form stable stem-loop structures (Fig. 3 and 4). In many cases, we were able to detect the predicted, approximately 70-nt precursors by Northern blotting (Fig. 1).

- 16 -

Some miRNA precursor sequences were also identified in mammalian cDNA (EST) databases [27], indicating that primary transcripts longer than 70-nt stem-loop precursors do also exist. We never cloned a 22-nt RNA complementary to any of the newly identified miRNAs, and it is as yet
5 unknown how the cellular processing machinery distinguishes between the miRNA and its complementary strand. Comparative analysis of the precursor stem-loop structures indicates that the loops adjacent to the base-paired miRNA segment can be located on either side of the miRNA sequence (Fig. 3 and 4), suggesting that the 5' or 3' location of the stem-
10 closing loop is not the determinant of miRNA excision. It is also unlikely that the structure, length or stability of the precursor stem is the critical determinant as the base-paired structures are frequently imperfect and interspersed by less stable, non-Watson-Crick base pairs such as G/A, U/U, C/U, A/A, and G/U wobbles. Therefore, a sequence-specific recognition
15 process is a likely determinant for miRNA excision, perhaps mediated by members of the Argonaute (rde-1/ago1/piwi) protein family. Two members of this family, alg-1 and alg-2, have recently been shown to be critical for stRNA processing in *C. elegans* [13]. Members of the Argonaute protein family are also involved in RNAi and PTGS. In *D. melanogaster*, these
20 include argonaute2, a component of the siRNA-endonuclease complex (RISC) [17], and its relative aubergine, which is important for silencing of repeat genes [18]. In other species, these include rde-1, argonaute1, and qde-2, in *C. elegans* [19], *Arabidopsis thaliana* [20], and *Neurospora crassa* [21], respectively. The Argonaute protein family therefore represents,
25 besides the RNase III Dicer [12, 13], another evolutionary link between RNAi and miRNA maturation.

Despite advanced genome projects, computer-assisted detection of genes encoding functional RNAs remains problematic [22]. Cloning of expressed,
30 short functional RNAs, similar to EST approaches (RNomics), is a powerful alternative and probably the most efficient method for identification of such novel gene products [23-26]. The number of functional RNAs has been

- 17 -

widely underestimated and is expected to grow rapidly because of the development of new functional RNA cloning methodologies.

The challenge for the future is to define the function and the potential
5 targets of these novel miRNAs by using bioinformatics as well as genetics,
and to establish a complete catalogue of time- and tissue-specific
distribution of the already identified and yet to be uncovered miRNAs. lin-4
and let-7 stRNAs negatively regulate the expression of proteins encoded by
mRNAs whose 3' untranslated regions contain sites of complementarity to
10 the stRNA [3-5].

Thus, a series of 33 novel genes, coding for 19- to 23-nucleotide
microRNAs (miRNAs), has been cloned from fly embryos and human cells.
Some of these miRNAs are highly conserved between vertebrates and
15 invertebrates and are developmentally or tissue-specifically expressed. Two
of the characterized human miRNAs may function as tumor suppressors in
B-cell chronic lymphocytic leukemia. miRNAs are related to a small class of
previously described 21- and 22-nt RNAs (lin-4 and let-7 RNAs), so-called
small temporal RNAs (stRNAs), and regulate developmental timing in C.
20 elegans and other species. Similar to stRNAs, miRNAs are presumed to
regulate translation of specific target mRNAs by binding to partially
complementary sites, which are present in their 3'-untranslated regions.

Deregulation of miRNA expression may be a cause of human disease, and
25 detection of expression of miRNAs may become useful as a diagnostic.
Regulated expression of miRNAs in cells or tissue devoid of particular
miRNAs may be useful for tissue engineering, and delivery or transgenic
expression of miRNAs may be useful for therapeutic intervention. miRNAs
may also represent valuable drug targets itself. Finally, miRNAs and their
30 precursor sequences may be engineered to recognize therapeutic valuable
targets.

- 18 -

EXAMPLE 2: miRNAs from mouse.

To gain more detailed insights into the distribution and function of miRNAs in mammals, we investigated the tissue-specific distribution of miRNAs in adult mouse. Cloning of miRNAs from specific tissues was preferred over whole organism-based cloning because low-abundance miRNAs that normally go undetected by Northern blot analysis are identified clonally. Also, in situ hybridization techniques for detecting 21-nt RNAs have not yet been developed. Therefore, 19- to 25-nucleotide RNAs were cloned and sequenced from total RNA, which was isolated from 18.5 weeks old BL6 mice. Cloning of miRNAs was performed as follows: 0.2 to 1 mg of total RNA was separated on a 15% denaturing polyacrylamide gel and RNA of 19- to 25-nt size was recovered. A 5'-phosphorylated 3'-adapter oligonucleotide (5'-pUUUaaccgcgaattccagx: uppercase, RNA; lowercase, DNA; p, phosphate; x, 3'-Amino-Modifier C-7, ChemGenes, Ashland, Ma, USA, Cat. No. NSS-1004; SEQ ID NO:54) and a 5'-adapter oligonucleotide (5'-acggaattcctcactAAA: uppercase, RNA; lowercase, DNA; SEQ ID NO:55) were ligated to the short RNAs. RT/PCR was performed with 3'-primer (5'-GACTAGCTGGAATTCGCGGTAAA; SEQ ID NO:56) and 5'-primer (5'-CAGCCAACGGAATTCCTCACTAAA; SEQ ID NO:57). In order to introduce Ban I restriction sites, a second PCR was performed using the primer pair 5'-CAGCCAACAGGCACCGAATTCCTCACTAAA (SEQ ID NO:57) and 5'-GACTAGCTTGGTGCCGAATTCGCGGTAAA (SEQ ID NO:56), followed by concatamerization after Ban I digestion and T4 DNA ligation. Concatamers of 400 to 600 basepairs were cut out from 1.5% agarose gels and recovered by Biotrap (Schleicher & Schuell) electroelution (1x TAE buffer) and by ethanol precipitation. Subsequently, the 3' ends of the concatamers were filled in by incubating for 15 min at 72°C with Taq polymerase in standard PCR reaction mixture. This solution was diluted 3-fold with water and directly used for ligation into pCR2.1 TOPO vectors. Clones were screened for inserts by PCR and 30 to 50 samples were subjected to sequencing. Because RNA was prepared from combining

- 19 -

tissues of several mice, minor sequence variations that were detected multiple times in multiple clones may reflect polymorphisms rather than RT/PCR mutations. Public database searching was used to identify the genomic sequences encoding the approx. 21-nt RNAs. The occurrence of
5 a 20 to 30 basepair fold-back structure involving the immediate upstream or downstream flanking sequences was used to assign miRNAs [36-38].

We examined 9 different mouse tissues and identified 34 novel miRNAs, some of which are highly tissue-specifically expressed (Table 3 and Figure
10 5). Furthermore, we identified 33 new miRNAs from different mouse tissues and also from human Soas-2 osteosarcoma cells (Table 4). miR-1 was previously shown by Northern analysis to be strongly expressed in adult heart, but not in brain, liver, kidney, lung or colon [37]. Here we show that miR-1 accounts for 45% of all mouse miRNAs found in heart, yet miR-1 was still expressed at a low level in liver and midbrain even
15 though it remained undetectable by Northern analysis. Three copies or polymorphic alleles of miR-1 were found in mice. The conservation of tissue-specific miR-1 expression between mouse and human provides additional evidence for a conserved regulatory role of this miRNA. In liver, variants of miR-122 account for 72% of all cloned miRNAs and miR-122
20 was undetected in all other tissues analyzed. In spleen, miR-143 appeared to be most abundant, at a frequency of approx. 30%. In colon, miR-142-as, was cloned several times and also appeared at a frequency of 30%. In small intestine, too few miRNA sequences were obtained to permit statistical analysis. This was due to strong RNase activity in this tissue,
25 which caused significant breakdown of abundant non-coding RNAs, e.g. rRNA, so that the fraction of miRNA in the cloned sequences was very low. For the same reason, no miRNA sequences were obtained from pancreas.

30

To gain insights in neural tissue miRNA distribution, we analyzed cortex, cerebellum and midbrain. Similar to heart, liver and small intestine, variants

- 20 -

of a particular miRNA, miR-124, dominated and accounted for 25 to 48% of all brain miRNAs. miR-101, -127, -128, -131, and -132, also cloned from brain tissues, were further analyzed by Northern blotting and shown to be predominantly brain-specific. Northern blot analysis was performed as described in Example 1. tRNAs and 5S rRNA were detected by ethidium staining of polyacrylamide gels prior to transfer to verify equal loading. Blots were stripped by boiling in deionized water for 5 min, and reprobed up to 4 times until the 21-nt signals became too weak for detection.

miR-125a and miR-125b are very similar to the sequence of *C. elegans* lin-4 stRNA and may represent its orthologs (Fig. 6A). This is of great interest because, unlike let-7 that was readily detected in other species, lin-4 has acquired a few mutations in the central region and thus escaped bioinformatic database searches. Using the mouse sequence miR-125b, we could readily identify its ortholog in the *D. melanogaster* genome. miR-125a and miR-125b differ only by a central diuridine insertion and a U to C change. miR-125b is very similar to lin-4 stRNA with the differences located only in the central region, which is presumed to be bulged out during target mRNA recognition [41]. miR-125a and miR-125b were cloned from brain tissue, but expression was also detected by Northern analysis in other tissues, consistent with the role for lin-4 in regulating neuronal remodeling by controlling lin-14 expression [43]. Unfortunately, orthologs to *C. elegans* lin-14 have not been described and miR-125 targets remain to be identified in *D. melanogaster* or mammals. Finally, miR-125b expression is also developmentally regulated and only detectable in pupae and adult but not in embryo or larvae of *D. melanogaster* (Fig. 6B).

Sequence comparison of mouse miRNAs with previously described miRNA reveals that miR-99b and miR-99a are similar to *D. melanogaster*, mouse and human miR-10 as well as *C. elegans* miR-51 [36], miR-141 is similar to *D. melanogaster* miR-8, miR-29b is similar to *C. elegans* miR-83, and miR-131 and miR-142-s are similar to *D. melanogaster* miR-4 and *C.*

- 21 -

elegans miR-79 [36]. miR-124a is conserved between invertebrates and vertebrates. In this respect it should be noted that for almost every miRNA cloned from mouse was also encoded in the human genome, and frequently detected in other vertebrates, such as the pufferfish, *Fugu rubripes*, and the zebrafish, *Danio rerio*. Sequence conservation may point to conservation in function of these miRNAs. Comprehensive information about orthologous sequences is listed in Fig. 7.

In two cases both strands of miRNA precursors were cloned (Table 3), which was previously observed once for a *C. elegans* miRNA [36]. It is thought that the most frequently cloned strand of a miRNA precursor represents the functional miRNA, which is miR-30c-s and miR-142-as, s and as indicating the 5' or 3' side of the fold-back structure, respectively.

The mir-142 gene is located on chromosome 17, but was also found at the breakpoint junction of a t(8;17) translocation, which causes an aggressive B-cell leukemia due to strong up-regulation of a translocated MYC gene [44]. The translocated MYC gene, which was also truncated at the first exon, was located only 4-nt downstream of the 3'-end of the miR-142 precursor. This suggests that translocated MYC was under the control of the upstream miR-142 promoter. Alignment of mouse and human miR-142 containing EST sequences indicate an approximately 20 nt conserved sequence element downstream of the mir-142 hairpin. This element was lost in the translocation. It is conceivable that the absence of the conserved downstream sequence element in the putative miR-142/mRNA fusion prevented the recognition of the transcript as a miRNA precursor and therefore may have caused accumulation of fusion transcripts and overexpression of MYC.

miR-155, which was cloned from colon, is excised from the known noncoding BIC RNA [47]. BIC was originally identified as a gene transcriptionally activated by promoter insertion at a common retroviral

- 22 -

integration site in B cell lymphomas induced by avian leukosis virus. Comparison of BIC cDNAs from human, mouse and chicken revealed 78% identity over 138 nucleotides [47]. The identity region covers the miR-155 fold-back precursor and a few conserved boxes downstream of the fold-back sequence. The relatively high level of expression of BIC in lymphoid organs and cells in human, mouse and chicken implies an evolutionary conserved function, but BIC RNA has also been detected at low levels in non-hematopoietic tissues [47].

Another interesting observation was that segments of perfect complementarity to miRNAs are not observed in mRNA sequences or in genomic sequences outside the miRNA inverted repeat. Although this could be fortuitous, based on the link between RNAi and miRNA processing [11, 13, 43] it may be speculated that miRNAs retain the potential to cleave perfectly complementary target RNAs. Because translational control without target degradation could provide more flexibility it may be preferred over mRNA degradation.

In summary, 63 novel miRNAs were identified from mouse and 4 novel miRNAs were identified from human Soas-2 osteosarcoma cells (Table 3 and Table 4), which are conserved in human and often also in other non-mammalian vertebrates. A few of these miRNAs appear to be extremely tissue-specific, suggesting a critical role for some miRNAs in tissue-specification and cell lineage decisions. We may have also identified the fruitfly and mammalian ortholog of *C. elegans* lin-4 stRNA. The establishment of a comprehensive list of miRNA sequences will be instrumental for bioinformatic approaches that make use of completed genomes and the power of phylogenetic comparison in order to identify miRNA-regulated target mRNAs.

References and Notes

1. R. C. Lee, R. L. Feinbaum, V. Ambros, *Cell* 75, 843 (1993).
2. B. J. Reinhart et al., *Nature* 403, 901 (2000).
- 5 3. V. Ambros, *Curr. Opin. Genet. Dev.* 10, 428 (2000).
4. E. G. Moss, *Curr. Biol.* 10, R436 (2000).
5. F. Slack, G. Ruvkun, *Annu. Rev. Genet.* 31, 611 (1997).
6. A. E. Pasquinelli et al., *Nature* 408, 86 (2000).
7. S. M. Elbashir et al., *Nature* 411, 494 (2001).
- 10 8. S. M. Elbashir, W. Lendeckel, T. Tuschl, *Genes & Dev.* 15, 188 (2001).
9. A. J. Hamilton, D. C. Baulcombe, *Science* 286, 950 (1999).
10. S. M. Hammond, E. Bernstein, D. Beach, G. J. Hannon, *Nature* 404, 293 (2000).
- 15 11. P. D. Zamore, T. Tuschl, P. A. Sharp, D. P. Bartel, *Cell* 101, 25 (2000).
12. G. Hutvagner, J. McLachlan, É. Bálint, T. Tuschl, P. D. Zamore, *Science* 93, 834 (2001).
13. A. Grishok et al., *Cell* 106, 23 (2001).
- 20 14. Cloning of 19- to 24-nt RNAs from *D. melanogaster* 0-2 h embryo lysate was performed as described (8). For cloning of HeLa miRNAs, 1 mg of HeLa total RNA was separated on a 15% denaturing polyacrylamide gel and RNA of 19- to 25-nt size was recovered. A 5' phosphorylated 3' adapter oligonucleotide (5' pUUU-aaccgcgaattccagx: uppercase, RNA; lowercase, DNA; p, phosphate; x, 4-hydroxymethylbenzyl; SEQ ID NO:54) and a 5' adapter oligonucleotide (5' acggaattcctcactAAA: uppercase, RNA; lowercase, DNA; SEQ ID NO:55) were ligated to the short HeLa cell RNAs. RT/PCR was performed with 3' primer (5' GACTAGCTGGAATTCGCGGTAAA; SEQ ID NO:56) and 5' primer (5' CAGCCAACGGAATTCCTCACTAAA; SEQ ID NO:57), and followed by concatamerization after Eco RI digestion and T4 DNA
- 30

- 24 -

ligation (8). After ligation of concatamers into pCR2.1 TOPO vectors, about 100 clones were selected and subjected to sequencing.

15. I. Schneider, *J Embryol Exp Morphol* 27, 353 (1972).
- 5 16. R. Feinbaum, V. Ambros, *Dev. Biol.* 210, 87 (1999).
17. S. M. Hammond, S. Boettcher, A. A. Caudy, R. Kobayashi, G. J. Hannon, *Science* 293, 1146 (2001).
18. A. A. Aravin et al., *Curr. Biol.* 11, 1017 (2001).
19. H. Tabara et al., *Cell* 99, 123 (1999).
- 10 20. M. Fagard, S. Boutet, J. B. Morel, C. Bellini, H. Vaucheret, *Proc. Natl. Acad. Sci. USA* 97, 11650 (2000).
21. C. Catalanotto, G. Azzalin, G. Macino, C. Cogoni, *Nature* 404, 245 (2000).
22. S. R. Eddy, *Curr. Opin. Genet. Dev.* 9, 695 (1999).
- 15 23. J. Cavaille et al., *Proc. Natl. Acad. Sci. USA* 97, 14311 (2000).
24. A. Hüttenhofer et al., *EMBO J.* 20, 2943 (2001).
25. L. Argaman et al., *Curr. Biol.* 11, 941 (2001).
26. K. M. Wassarman, F. Repoila, C. Rosenow, G. Storz, S. Gottesman, *Genes & Dev.* 15, 1637 (2001).
- 20 27. Supplementary Web material is available on Science Online at www.sciencemag.org/cgi/content/full/xxx
28. D. H. Mathews, J. Sabina, M. Zuker, D. H. Turner, *J. Mol. Biol.* 288, 911 (1999).
29. E. Bernstein, A. A. Caudy, S. M. Hammond, G. J. Hannon, *Nature* 25 409, 363 (2001).
30. Graham, F.L. and van der Eb, A.J., (1973), *Virology* 52, 456.
31. McCutchan, J.H. and Pagano, J.S., (1968), *J. Natl. Cancer Inst.* 41, 351.
32. Chu, G. et al., (1987), *Nucl. Acids Res.* 15, 1311.
- 30 33. Fraley, R. et al., (1980), *J. Biol. Chem.* 255, 10431.
34. Capecchi, M.R., (1980), *Cell* 22, 479.
35. Felgner, P.L. et al., (1987), *Proc. Natl. Acad. Sci USA* 84, 7413.

- 25 -

36. Lau N.C., Lim L.P., Weinstein E.G., Bartel D.P., (2001), *Science* 294, 858-862.
37. Lee R.C., Ambros V., (2001), *Science* 294, 862-864.
38. Ambros V., (2001), *Cell* 107, 823-826.
- 5 39. Ambros V., Horvitz H.R., (1984), *Science* 226, 409-416.
40. Wightman B., Ha I., Ruvkun G., (1993), *Cell* 75, 855-862.
41. Rougvie A.E., (2001), *Nat. Rev. Genet.* 2, 690-701.
42. Ketting R.F., Fischer S.E., Bernstein E., Sijen T., Hannon G.J.,
Plasterk R.H., (2001), *Genes & Dev.* 15, 2654-2659.
- 10 43. Hallam S.J., Jin Y., (1998), *Nature* 395, 78-82.
44. Gauwerky C.E., Huebner K., Isobe M., Nowell P.C., Croce C.M.,
(1989), *Proc. Natl. Acad. Sci. USA* 86, 8867-8871.
45. P. Chomczynski, N. Sacchi, *Anal Biochem* 162, 156, (1987).
46. Mourelatos Z., Dostie J., Paushkin S., Sharma A., Charroux B., Abel
15 L., J.R., Mann M., Dreyfuss G., (2002), *Genes & Dev.*, in press.
47. Tam W., (2001), *Gene* 274, 157-167.

Table 1

D. melanogaster miRNAs. The sequences given represent the most abundant, and typically longest miRNA sequence identified by cloning; miRNAs frequently vary in length by one or two nucleotides at their 3' termini. From 222 short RNAs sequenced, 69 (31%) corresponded to miRNAs, 103 (46%) to already characterized functional RNAs (rRNA, 7SL RNA, tRNAs), 30 (14%) to transposon RNA fragments, and 20 (10%) sequences with no database entry. The frequency (freq.) for cloning a particular miRNA relative to all identified miRNAs is indicated in percent.

Results of Northern blotting of total RNA isolated from staged populations of D. melanogaster are summarized. E, embryo; L, larval stage; P, pupae; A, adult; S2, Schneider-2 cells. The strength of the signal within each blot is represented from strongest (+++) to undetected (-). let-7 stRNA was probed as control. Genbank accession numbers and homologs of miRNAs identified by database searching in other species are provided as supplementary material.

miRNA	sequence (5' to 3')	freq. (%)	E 0-3 h	E 0-6 h	L1+ L2	L3	P	A	S2
miR-1	UGGAAUGUAAAGAAGUAUGGAG (SEQ ID NO:58)	32	+	+	++ +	++ +	++	++ +	-
miR-2a*	UAUCACAGCCAGCUUGAUGAGC (SEQ ID NO:59)	3							
miR-2b*	UAUCACAGCCAGCUUGAGGAGC (SEQ ID NO:60)	3	++	++	++ +	++ +	++	+	++ +
miR-3	UCACUGGGCAAAGUGUGUCUCA#	9	+++	+++	-	-	-	-	-
miR-4	AUAAAGCUAGACAACCAUUGA (SEQ ID NO:62)	6	+++	+++	-	-	-	-	-
miR-5	AAAGGAACGAUCGUUGUGAU AUG (SEQ ID NO:63)	1	+++	+++	+/-	+/-	-	-	-
miR-6	UAUCACAGUGGCUGUUCUUUUU (SEQ ID NO:64)	13	+++	+++	+/-	+/-	-	-	-
miR-7	UGGAAGACUAGUGAUUUUGUUGU (SEQ ID NO:65)	4	+++	++	+/-	+/-	+/-	+/-	+/-
miR-8	UAAUACUGUCAGGUAAGAUGUC (SEQ ID NO:66)	3	+/-	+/-	++ +	++ +	+	++ +	-

- 27 -

miR-9	UCUUUGGUUAUCUAGCUGUAUGA (SEQ ID NO:67)	7	+++	++	++	++	++	++	+/-	-
miR-10	ACCCUGUAGAUCGAAUUUGU (SEQ ID NO:68)	1	+	+	++	++	++	++	+	-
miR-11	CAUCACAGUCUGAGUUCUUGC (SEQ ID NO:69)	7	+++	+++	++	++	++	++	+	-
miR-12	UGAGUAAUACAUCAGGUACUGGU (SEQ ID NO:70)	7	+	+	++	++	++	++	+	+/-
5 miR-13a*	UAUCACAGCCAUUUUGACGAGU (SEQ ID NO:71)	1	+++	+++	++	++	++	++	++	++
miR-13b*	UAUCACAGCCAUUUUGAUGAGU (SEQ ID NO:72)	0								
miR-14	UCAGUCUUUUUCUCUCUCCUA (SEQ ID NO:73)	1	-	-	-	-	-	-	-	-
let-7	UGAGGUAGUAGGUUGUAUAGUU (SEQ ID NO:74)	0	-	-	-	-	++	++	++	-

10 # = (SEQ ID NO:61)

*Similar miRNA sequences are difficult to distinguish by Northern blotting because of potential cross-hybridization of probes.

- 28 -

Table 2

Human miRNAs. From 220 short RNAs sequenced, 100 (45%) corresponded to miRNAs, 53 (24%) to already characterized functional RNAs (rRNA, snRNAs, tRNAs), and 67 (30%) sequences with no database entry. Results of Northern blotting of total RNA isolated from different vertebrate species and S2 cells are indicated. For legend, see Table 1.

miRNA	sequence (5' to 3')	freq. (%)	HeLa cells	mouse kidney	adult fish	frog ovary	S2
let-7a*	UGAGGUAGUAGGUUGUAUAGUU#	10	+++	+++	+++	-	-
10 let-7b*	UGAGGUAGUAGGUUGUGUGUU (SEQ ID NO:76)	13					
let-7c*	UGAGGUAGUAGGUUGUAUGGUU (SEQ ID NO:77)	3					
let-7d*	AGAGGUAGUAGGUUGCAUAGU (SEQ ID NO:78)	2	+++	+++	+++	-	-
let-7e*	UGAGGUAGGAGGUUGUAUAGU (SEQ ID NO:79)	2	+++	+++	+++	-	-
let-7f*	UGAGGUAGUAGAUUGUAUAGUU (SEQ ID NO:80)	1					
15 miR-15	UAGCAGCACAAUAAUGGUUGUG (SEQ ID NO:81)	3	+++	++	+	+/-	-
miR-16	UAGCAGCACGUAUAAUUGGCG (SEQ ID NO:82)	10	+++	+	+/-	+/-	-
miR-17	ACUGCAGUGAAGGCACUUGU (SEQ ID NO:83)	1	+++	-	-	-	-
miR-18	UAAGGUGCAUCUAGUGCAGUA (SEQ ID NO:84)	2	+++	-	-	-	-
miR-19a*	UGUGCAAUUCUAUGCAAAACUGA (SEQ ID NO:85)	1	+++	-	+/-	-	-
20 miR-19b*	UGUGCAAUCCAUGCAAAACUGA (SEQ ID NO:86)	3					
miR-20	UAAAGUGCUUAUAGUGCAGGUA (SEQ ID NO:87)	4	+++	-	+	-	-
miR-21	UAGCUUAUCAGACUGAUGUUGA (SEQ ID NO:88)	10	+++	+	++	-	-
miR-22	AAGCUGCCAGUUGAAGAACUGU (SEQ ID NO:89)	10	+++	+++	+	+/-	-
miR-23	AUCACAUUGCCAGGGAUUUCC (SEQ ID NO:90)	2	+++	+++	+++	+	-

- 29 -

	miR-24	UGGCUCAGUUCAGCAGGAACAG (SEQ ID NO:91)	4	++	+++	++	-	-
	miR-25	CAUUGCACUUGUCUCGGUCUGA (SEQ ID NO:92)	3	+++	+	++	-	-
	miR-26a*	UUCAAGUAAUCCAGGAUAGGCU (SEQ ID NO:93)	2	+	++	+++	-	-
	miR-26b*	UUCAAGUAAUCCAGGAUAGGUU (SEQ ID NO:94)	1					-
5	miR-27	UUCACAGUGGCUAAGUCCGCU (SEQ ID NO:95)	2	+++	+++	++	-	-
	miR-28	AAGGAGCUCACAGUCUAUUGAG (SEQ ID NO:96)	2	+++	+++	-	-	-
	miR-29	CUAGCACCAUCUGAAUCCGUU (SEQ ID NO:97)	2	+	+++	+/-	-	-
	miR-30	CUUUCAGUCGGAUGUUUGCAGC (SEQ ID NO:98)	2	+++	+++	+++	-	-
	miR-31	GGCAAGAUGCUGGCAUAGCUG (SEQ ID NO:99)	2	+++	-	-	-	-
10	miR-32	UAUUGCACAUUACUAAGUUGC (SEQ ID NO:100)	1	-	-	-	-	-
	miR-33	GUGCAUUGUAGUUGCAUUG (SEQ ID NO:101)	1	-	-	-	-	-
	miR-1	UGGAAUGUAAAGAAGUAUGGAG (SEQ ID NO:102)	0	-	-	+	-	-
	miR-7	UGGAAGACUAGUGAUUUUGUUGU (SEQ ID NO:103)	0	+	-	+/-	-	+/-
	miR-9	UCUUUGGUUAUCUAGCUGUAUGA (SEQ ID NO:104)	0	-	-	-	-	-
15	miR-10	ACCCUGUAGAUCCGAAUUGU (SEQ ID NO:105)	0	-	+	-	-	-

= (SEQ ID NO:75)

* Similar miRNA sequences are difficult to distinguish by Northern
 20 blotting because of potential cross-hybridization of probes.

- 30 -

Table 3

Mouse miRNAs. The sequences indicated represent the longest miRNA sequences identified by cloning. The 3'-terminus of miRNAs is often truncated by one or two nucleotides. miRNAs that are more than 85% identical in sequence (i.e. share 18 out of 21 nucleotides) or contain 1- or 2-nucleotide internal deletions are referred to by the same gene number followed by a lowercase letter. Minor sequence variations between related miRNAs are generally found near the ends of the miRNA sequence and are thought to not compromise target RNA recognition. Minor sequence variations may also represent A to G and C to U changes, which are accommodated as G-U wobble base pairs during target recognition. miRNAs with the suffix -s or -as indicate RNAs derived from either the 5'-half or the 3'-half of a miRNA precursor. Mouse brains were dissected into midbrain, mb, cortex, cx, cerebellum, cb. The tissues analyzed were heart, ht; liver, lv; small intestine, si; colon, co; cortex, ct; cerebellum, cb; midbrain, mb.

	miRNA	sequence (5' to 3')	Number of clones							
			ht	lv	sp	si	co	cx	cb	mb
20	let-7a	UGAGGUAGUAGGUUGUAUAGUU (SEQ ID NO:106)		3			1	1		7
	let-7b	UGAGGUAGUAGGUUGUGUGGUU (SEQ ID NO:107)		1	1				2	5
	let-7c	UGAGGUAGUAGGUUGUAUGGUU (SEQ ID NO:108)		2				2	5	19
	let-7d	AGAGGUAGUAGGUUGCAUAGU (SEQ ID NO:109)	2				2	2		2
25	let-7e	UGAGGUAGGAGGUUGUAUAGU (SEQ ID NO:110)			1					2
	let-7f	UGAGGUAGUAGAUUGUAUAGUU (SEQ ID NO:111)			2				3	3
	let-7g	UGAGGUAGUAGUUUGUACAGUA (SEQ ID NO:112)						1	1	2
	let-7h	UGAGGUAGUAGUGUGUACAGUU (SEQ ID NO:113)						1	1	

- 31 -

	let-7i	UGAGGUAGUAGUUUGUGCU (SEQ ID NO:114)				1	1		
	miR-1b	UGGAAUGUAAAGAAGUAUGUAA (SEQ ID NO:115)	4	2					1
	miR-1c	UGGAAUGUAAAGAAGUAUGUAC (SEQ ID NO:116)	7						
	miR-1d	UGGAAUGUAAAGAAGUAUGUAUU (SEQ ID NO:117)	16						1
5	miR-9	UCUUUGGUUAUCUAGCUGUAUGA (SEQ ID NO:118)				3	4	4	
	miR-15a	UAGCAGCACAUAAUGGUUUUGUG (SEQ ID NO:119)	1						2
	miR-15b	UAGCAGCACAUCAUGGUUUACA (SEQ ID NO:120)	1						
	miR-16	UAGCAGCACGUAAAUAUUGGCG (SEQ ID NO:121)	1			1	2	1	2
	miR-18	UAAGGUGCAUCUAGUGCAGUA (SEQ ID NO:122)			1				
10	miR-19b	UGUGCAAAUCCAUGCAAACUGA (SEQ ID NO:123)			1				
	miR-20	UAAAGUGCUUAUAGUGCAGGUAG (SEQ ID NO:124)				1			
	miR-21	UAGCUUAUCAGACUGAUGUUGA (SEQ ID NO:125)	1		1	2	1		
	miR-22	AAGCUGCCAGUUGAAGAACUGU (SEQ ID NO:126)	2	1		1		1	2
	miR-23a	AUCACAUUGCCAGGGAUUUCC (SEQ ID NO:127)	1						
15	miR-23b	AUCACAUUGCCAGGGAUUACCAC (SEQ ID NO:128)					1		
	miR-24	UGGCUCAGUUCAGCAGGAACAG (SEQ ID NO:129)	1			1	1		1
	miR-26a	UUCAAGUAAUCCAGGAUAGGCU (SEQ ID NO:130)						3	2
	miR-26b	UUCAAGUAAUCCAGGAUAGGUU (SEQ ID NO:131)		2			4	1	
	miR-27a	UUCACAGUGGCUAAGUUCGCU (SEQ ID NO:132)	1		2		1	1	2
20	miR-27b	UUCACAGUGGCUAAGUUCUG (SEQ ID NO:133)							1
	miR-29a	CUAGCACCAUCUGAAAUCGGUU (SEQ ID NO:134)	1			1		1	
	miR-29b/miR-102	UAGCACCAUUUGAAAUCAGUGUU (SEQ ID NO:135)	1			1	5		3
	miR-29c/	UAGCACCAUUUGAAAUCGGUUA (SEQ ID NO:136)	1				3		1

- 32 -

	miR-30a-s/miR-97	UGUAAACAUCUCCUGACUGGAAGC (SEQ ID NO:137)	1		1		1
	miR-30a-as ^a	CUUUCAGUCGGAUGUUUGCAGC (SEQ ID NO:138)				1	
	miR-30b	UGUAAACAUCUACACUCAGC (SEQ ID NO:139)	1			2	
	miR-30c	UGUAAACAUCUACACUCUCAGC (SEQ ID NO:140)	2		1		1
5	miR-30d	UGUAAACAUCUCCCGACUGGAAG (SEQ ID NO:141)	1				
	miR-99a/miR-99	ACCCGUAGAUCGUAUCUUGU (SEQ ID NO:142)			1		
	miR-99b	CACCCGUAGAACCGACCUUGCG (SEQ ID NO:143)				1	
	miR-101	UACAGUACUGUGAUAAACUGA (SEQ ID NO:144)			2	1	1
	miR-122a	UGGAGUGUGACAAUGGUGUUUGU (SEQ ID NO:145)	3				
10	miR-122b	UGGAGUGUGACAAUGGUGUUUGA (SEQ ID NO:146)	11				
	miR-122a,b	UGGAGUGUGACAAUGGUGUUUG (SEQ ID NO:147)	23				
	miR-123	CAUUAUUACUUUUGGUACGCG (SEQ ID NO:148)	1	2			
	miR-124a ^b	UUAAGGCACGCGG-UGAAUGCCA (SEQ ID NO:149)		1	37	41	24
	miR-124b	UUAAGGCACGCGGGUGAAUGC (SEQ ID NO:150)			1	3	
15	miR-125a	UCCCUGAGACCCUUUAACCUUG (SEQ ID NO:151)			1	1	
	miR-125b	UCCCUGAGACCCU--AACUUGUGA (SEQ ID NO:152)			1		
	miR-126	UCGUACCGUGAGUAAUAAUGC (SEQ ID NO:153)	4			1	
	miR-127	UCGGAUCCGUCUGAGCUUGGCU (SEQ ID NO:154)				1	
	miR-128	UCACAGUGAACCGGUCUCUUUU (SEQ ID NO:155)			2	2	2
20	miR-129	CUUUUUUCGGUCUGGGCUUGC (SEQ ID NO:156)				1	
	miR-130	CAGUGCAAUGUAAAAGGGC (SEQ ID NO:157)				1	
	miR-131	UAAAGCUAGAUAAACCGAAAGU (SEQ ID NO:158)			1	1	1
	miR-132	UAAACAGUCUACAGCCAUGGUCGU (SEQ ID NO:159)				1	

- 33 -

	miR-133	UUGGUCCCCUUAACCAGCUGU (SEQ ID NO:160)	4			1	
	miR-134	UGUGACUGGUUGACCAGAGGGA (SEQ ID NO:161)				1	
	miR-135	UAUGGCUUUUUAUCCUAUGUGAA (SEQ ID NO:162)				1	
	miR-136	ACUCCAUUUGUUUUGAUGAUGGA (SEQ ID NO:163)				1	
5	miR-137	UAUUGCUUAAGAAUACGCGUAG (SEQ ID NO:164)				1	1
	miR-138	AGCUGGUGUUGUGAAUC (SEQ ID NO:165)				1	
	miR-139	UCUACAGUGCACGUGUCU (SEQ ID NO:166)				1	1
	miR-140	AGUGGUUUUACCCUAUGGUAG (SEQ ID NO:167)			1		
	miR-141	AACACUGUCUGGUAAGAUGG (SEQ ID NO:168)		1	1		1
10	miR-142-s	CAUAAAGUAGAAAGCACUAC (SEQ ID NO:169)			1	1	
	miR-142-as ^b	UGUAGUGUUCCUACUUUAUGG (SEQ ID NO:170)		1	1	6	
	miR-143	UGAGAUGAAGCACUGUAGCUCA (SEQ ID NO:171)	3	7		2	1
	miR-144	UACAGUAUAGAUGAUGUACUAG (SEQ ID NO:172)	2			1	
	miR-145	GUCCAGUUUCCCAGGAAUCCCUU (SEQ ID NO:173)	1				
15	miR-146	UGAGAACUGAAUCCAUGGGUUU (SEQ ID NO:174)	1				
	miR-147	GUGUGUGGAAAUGCUUCUGCC (SEQ ID NO:175)		1			
	miR-148	UCAGUGCACUACAGAACUUUGU (SEQ ID NO:176)		1			
	miR-149	UCUGGCUCCGUGUCUACUCC (SEQ ID NO:177)	1				
	miR-150	UCUCCCAACCCUUGUACCAGUGU (SEQ ID NO:178)				1	
20	miR-151	CUAGACUGAGGCUCUUGAGGU (SEQ ID NO:179)				1	
	miR-152	UCAGUGCAUGACAGAACUUGG (SEQ ID NO:180)				1	
	miR-153	UUGCAUAGUCACAAAAGUGA (SEQ ID NO:181)					1
	miR-154	UAGGUUAUCCGUGUUGCCUUG (SEQ ID NO:182)					1

- 34 -

miR-155

UUAAUGCUAAUUGUGAUAGGGG
(SEQ ID NO:183)1

5 ^aThe originally described miR-30 was renamed to miR-30a-as in order to distinguish it from the miRNA derived from the opposite strand of the precursor encoded by the mir-30a gene. miR-30a-s is equivalent to miR-97 [46].

^bA 1-nt length heterogeneity is found on both 5' and 3' end. The 22-nt miR sequence is shown, but only 21-nt miRNAs were cloned.

10

Table 4

Mouse and human miRNAs. The sequences indicated represent the longest miRNA sequences identified by cloning. The 3' terminus of miRNAs is often truncated by one or two nucleotides. miRNAs that are more than 85% identical in sequence (i.e. share 18 out of 21 nucleotides) or contain 1- or 2-nucleotide internal deletions are referred to by the same gene number followed by a lowercase letter. Minor sequence variations between related miRNAs are generally found near the ends of the miRNA sequence and are thought to not compromise target RNA recognition. Minor sequence variations may also represent A to G and C to U changes; which are accommodated as G-U wobble base pairs during target recognition. Mouse brains were dissected into midbrain, mb, cortex, cx, cerebellum, cb. The tissues analyzed were lung, ln; liver, lv; spleen, sp; kidney, kd; skin, sk; testis, ts; ovary, ov; thymus, thy; eye, ey; cortex, ct; cerebellum, cb; midbrain, mb. The human osteosarcoma cells SAOS-2 cells contained an inducible p53 gene (p53-, uninduced p53; p53+, induced p53); the differences in miRNAs identified from induced and uninduced SAOS cells were not statistically significant.

[illegible]

miR-C15	UACCACAGGGUAGAAACCACGGA	1			(SEQ ID NO.198)
miR-C16	AACUGGCCUACAAAGUCCCGAG	1			(SEQ ID NO.199)
miR-C17	UGUAAACAGCAACUCCAUGUGGA	1			(SEQ ID NO.200)
miR-C18	UAGCAGCACAGAAAUUUGGC	2	1		(SEQ ID NO.201)
5 miR-C19	UAGGUAGUUUCAUGUUGUUGG			1	(SEQ ID NO.202)
miR-C20	UUCRACCAACCUUCCUCCACCCAGC		1		(SEQ ID NO.203)
miR-C21	GGUCCAGAGGGGAGAUAGG			1	(SEQ ID NO.204)
miR-C22	CCCAGUGUUUCAGACUACCUGUU			1	(SEQ ID NO.205)
miR-C23	UAAUACUGCCUGGUAAUGAUGAC	2		1	(SEQ ID NO.206)
10 miR-C24	UACUCAGUAAAGGCAUUGUUCU			1	(SEQ ID NO.207)
miR-C25	AGAGUAUAAGCGCAUGGGAAGA			1	(SEQ ID NO.208)
miR-C26	UGAAAUGUUUUAAGGACCACUAG			1	(SEQ ID NO.209)
miR-C27	UUCUUUUGUCAUCCUAUGCCUG			1	(SEQ ID NO.210)
miR-C28	UCCUUAUCCACCGGAGUCUG				(SEQ ID NO.211)
15 miR-C29	GUGAAAUGUUUUAAGGACCACUAGA	2			(SEQ ID NO.212)
miR-C30	UGGAAUGUAAGGAAGUGUGUGG	2			(SEQ ID NO.213)
miR-C31	UACAGUAGUCUGCACAUUGGUU	1			(SEQ ID NO.214)
miR-C32	CCCUGUAGAACCGAAUUUGUGU	1		1	(SEQ ID NO.215)
miR-C33	AACCCGUAGAUCCGAAAUUGUGAA	1			(SEQ ID NO.216)
20 miR-C34	GCUUCUCCUGGCUCUCCUCCUC		1		(SEQ ID NO.217)

Table 5

D. melanogaster miRNA sequences and genomic location. The sequences given represent the most abundant, and typically longest miRNA sequences identified by cloning. It was frequently observed that miRNAs vary in length by one or two nucleotides at their 3'-terminus. From 222 short RNAs sequenced; 69 (31%) corresponded to miRNAs, 103 (46%) to already characterized functional RNAs (rRNA, 7SL RNA, tRNAs), 30 (14%) to transposon RNA fragments, and 20 (10%) sequences with no database entry. RNA sequences with a 5'-guanosine are likely to be underrepresented due to the cloning procedure (8). miRNA homologs found in other species are indicated. Chromosomal location (chr.) and GenBank accession numbers (acc. nb.) are indicated. No ESTs matching miR-1 to miR-14 were detectable by database searching.

miRNA	sequence (5' to 3')	chr., acc. nb.	remarks
miR-1	UGGAAUGUAAAGAAGUAUGGAG (SEQ ID NO:58)	2L, AE003667	homologs: <i>C. briggsae</i> , G20U, AC87074; <i>C.elegans</i> G20U, U97405; mouse, G20U, G22U, AC020867; human, chr. 20, G20U, G22U, AL449263; ESTs: zebrafish, G20U, G22U, BF157-601; cow, G20U, G22U, BE722-224; human, G20U, G22U, AI220268
miR-2a	UAUCACAGCCAGCUUUGAUGAGC (SEQ ID NO:59)	2L, AE003663	2 precursor variants clustered with a copy of <i>mir-2b</i>
miR-2b	UAUCACAGCCAGCUUUGAGGAGC (SEQ ID NO:60)	2L, AE003620 2L, AE003663	2 precursor variants
miR-3	UCACUGGGCAAAGUGUGUCUCA (SEQ ID NO:61)	2R, AE003795	in cluster <i>mir-3</i> to <i>mir-6</i>
miR-4	AUAAAGCTAGACAACCAUUGA (SEQ ID NO:62)	2R, AE003795	in cluster <i>mir-3</i> to <i>mir-6</i>

- 39 -

	miR-5	AAAGGAACGAUCGUUGUGAU AUG (SEQ ID NO:63)	2R, AE003795	in cluster <i>mir-3</i> to <i>mir-6</i>
	miR-6	UAUCACAGUGGCGUUCUUUUU (SEQ ID NO:64)	2R, AE003795	in cluster <i>mir-3</i> to <i>mir-6</i> with 3 variants
5	miR-7	UGGAAGACUAGUGAUUUUGUUGU (SEQ ID NO:65)	2R, AE003791	homologs: human, chr. 19 AC006537, EST BF373391; mouse chr. 17 AC026385, EST AA881786
	miR-8	UAAUACUGUCAGGUAAAGAUGUC (SEQ ID NO:66)	2R, AE003805	
10	miR-9	UCUUUGGUUAUCUAGCUGUAUGA (SEQ ID NO:67)	3L, AE003516	homologs: mouse, chr. 19, AF155142; human, chr. 5, AC026701, chr. 15, AC005316
	miR-10	ACCCUGUAGAUCGAAUUUGU (SEQ ID NO:68)	AE001574	homologs: mouse, chr 11, AC011194; human, chr. 17, AF287967
	miR-11	CAUCACAGUCUGAGUUCUUGC (SEQ ID NO:69)	3R, AE003735	intronic location
15	miR-12	UGAGUAUUACAUCAGGUACUGGU (SEQ ID NO:70)	X, AE003499	intronic location
	miR-13a	UAUCACAGCCAUUUUGACGAGU (SEQ ID NO:71)	3R, AE003708 X, AE003446	<i>mir-13a</i> clustered with <i>mir-13b</i> on chr. 3R
20	miR-13b	UAUCACAGCCAUUUUGAUGAGU (SEQ ID NO:72)	3R, AE003708	<i>mir-13a</i> clustered with <i>mir-13b</i> on chr. 3R
	miR-14	UCAGUCUUUUUCUCUCUCCUA (SEQ ID NO:73)	2R, AE003833	no signal by Northern analysis

Table 6

Human miRNA sequences and genomic location. From 220 short RNAs sequenced, 100 (45%) corresponded to miRNAs, 53 (24%) to already characterized functional RNAs (rRNA, snRNAs, tRNAs), and 67 (30%) sequences with no database entry. For legend, see Table 1.

miRNA	sequence (5' to 3')	chr. or EST, acc. nb.	remarks*
10 let-7a	UGAGGUAGUAGGUUGUAUAGUU (SEQ ID NO:75)	9, AC007924, 11, AP001359, 17, AC087784, 22, AL049853	sequences of chr 9 and 17 identical and clustered with <i>let-7f</i> , homologs: <i>C. elegans</i> , AF274345; <i>C. briggsae</i> , AF210771, <i>D. melanogaster</i> , AE003659
let-7b	UGAGGUAGUAGGUUGUGUGGUU (SEQ ID NO:76)	22, AL049853†, ESTs, AI382133, AW028822	homologs: mouse, EST AI481799; rat, EST, BE120662
let-7c	UGAGGUAGUAGGUUGUAUGGUU (SEQ ID NO:77)	21, AP001667	Homologs: mouse, EST, AA575575
15 let-7d	AGAGGUAGUAGGUUGCAUAGU (SEQ ID NO:78)	17, AC087784, 9, AC007924	identical precursor sequences
let-7e	UGAGGUAGGAGGUUGUAUAGU (SEQ ID NO:79)	19, AC018755	
20 let-7f	UGAGGUAGUAGAUGUAUAGUU (SEQ ID NO:80)	9, AC007924, 17, AC087784, X, AL592046	sequences of chr 9 and 17 identical and clustered with <i>let-7a</i>
miR-15	UAGCAGCACAUAAUGGUUUGUG (SEQ ID NO:81)	13, AC069475	in cluster with <i>mir-16</i> homolog
miR-16	UAGCAGCACGUAAAUAUUGGCG (SEQ ID NO:82)	13, AC069475	in cluster with <i>mir-15</i> homolog

- 41 -

	miR-17	ACUGCAGUGAAGGCACUUGU (SEQ ID NO:83)	13, AL138714	in cluster with <i>mir-17</i> to <i>mir-20</i>
	miR-18	UAAGGUGCAUCUAGUGCAGAU (SEQ ID NO:84)	13, AL138714	in cluster with <i>mir-17</i> to <i>mir-20</i>
5	miR-19a	UGUGCAAUUCUAUGCAAACUG A (SEQ ID NO:85)	13, AL138714	in cluster with <i>mir-17</i> to <i>mir-20</i>
	miR-19b	UGUGCAAUCCAUGCAAACUG A (SEQ ID NO:86)	13, AL138714, X, AC002407	in cluster with <i>mir-17</i> to <i>mir-20</i>
	miR-20	UAAAGUGCUUAUAGUGCAGGUA (SEQ ID NO:87)	13, AL138714	in cluster with <i>mir-17</i> to <i>mir-20</i>
10	miR-21	UAGCUUAUCAGACUGAUGUUGA (SEQ ID NO:88)	17, AC004686, EST, BF326048	homologs: mouse, EST, AA209594
	miR-22	AAGCUGCCAGUUGAAGAACUGU (SEQ ID NO:89)	ESTs, AW961681†, AA456477, AI752503, BF030303, HS1242049	human ESTs highly similar; homologs: mouse, ESTs, e.g. AA823029; rat, ESTs, e.g. BF543690
15	miR-23	AUCACAUUGCCAGGGAUUUC (SEQ ID NO:90)	19, AC020916	homologs: mouse, EST, AW124037; rat, EST, BF402515
	miR-24	UGGCUCAGUUCAGCAGGAACAG (SEQ ID NO:91)	9, AF043896, 19, AC020916	homologs: mouse, ESTs, AA111466, AI286629; pig, EST, BE030976
20	miR-25	CAUUGCACUUGUCUCGGUCUGA (SEQ ID NO:92)	7, AC073842, EST, BE077684	human chr 7 and EST identical; highly similar precursors in mouse ESTs (e.g. AI595464); fish precursor different STS: G46757
	miR-26a	UUCAAGUAAUCCAGGAUAGGCU (SEQ ID NO:93)	3, AP000497	

- 42 -

	miR-26b	UUCAAGUAAUUCAGGAUAGGUU (SEQ ID NO:94)	2, AC021016	
	miR-27	UUCACAGUGGCUAAGUCCGCU (SEQ ID NO:95)	19, AC20916	U22C mutation in human genomic sequence
5	miR-28	AAGGAGCUCACAGUCUAUUGAG (SEQ ID NO:96)	3, AC063932	
	miR-29	CUAGCACCAUCUGAAAUCGGUU (SEQ ID NO:97)	7, AF017104	
	miR-30	CUUUCAGUCGGAUGUUUGCAGC (SEQ ID NO:98)	6, AL035467	
10	miR-31	GGCAAGAUGCUGGCAUAGCUG (SEQ ID NO:99)	9, AL353732	
	miR-32	UAUUGCACAUUACUAAGUUGC (SEQ ID NO:100)	9, AL354797	not detected by Northern blotting
15	miR-33	GUGCAUUGUAGUUGCAUUG (SEQ ID NO:101)	22, Z99716	not detected by Northern blotting

*If several ESTs were retrieved for one organism in the database, only those with different precursor sequences are listed.

20 †precursor structure shown in Fig. 4.

- 43 -

Claims

1. Isolated nucleic acid molecule comprising
 - (a) a nucleotide sequence as shown in Table 1, Table 2, Table 3 or Table 4 or a precursor thereof as shown in Figure 3, Figure 4 or Figure 7.
 - (b) a nucleotide sequence which is the complement of (a),
 - (c) a nucleotide sequence which has an identity of at least 80% to a sequence of (a) or (b) and/or
 - (d) a nucleotide sequence which hybridizes under stringent conditions to a sequence of (a), (b) and/or (c).
2. The nucleic acid molecule of claim 1, wherein the identity of sequence (c) is at least 90%.
3. The nucleic acid molecule of claim 1, wherein the identity of sequence (c) is at least 95%.
4. The nucleic acid molecule of any one of claims 1-3, which is selected from miR 1-14 as shown in Table 1 or miR 15-33 as shown in Table 2 or miR 1-155 as shown in Table 3 or miR-C1-34 as shown in Table 4 or a complement thereof.
5. The nucleic acid molecule of any one of claims 1-3, which is selected from mir 1-14 as shown in Figure 3 or let 7a-7f or mir 15-33, as shown in Figure 4 or let 7a-i or mir 1-155 or mir-c1-34, as shown in Figure 7 or a complement thereof.

- 44 -

6. The nucleic acid molecule of any one of claims 1-4 which is a miRNA molecule or an analog thereof having a length of from 18-25 nucleotides.
7. The nucleic acid molecule of any one of claims 1-3 or 5, which is a
5 miRNA precursor molecule having a length of 60-80 nucleotides or a DNA molecule coding therefor.
8. The nucleic acid molecule of any one of claims 1-7, which is single-stranded.
- 10 9. The nucleic acid molecule of any one of claims 1-7, which is at least partially double-stranded.
- 15 10. The nucleic acid molecule of any one of claims 1-9, which is selected from RNA, DNA or nucleic acid analog molecules.
11. The nucleic acid molecule of claim 10, which is a molecule containing at least one modified nucleotide analog.
- 20 12. The nucleic molecule of claim 10 which is a recombinant expression vector.
13. A pharmaceutical composition containinig as an active agent at least one nucleic acid molecule of any one of claims 1-12 and optionally a pharma-
25 ceutically acceptable carrier.
14. The composition of claim 13 for diagnostic applications.
15. The composition of claim 13 for therapeutic applications.
- 30 16. The composition of any one of claims 13-15 as a marker or a modulator for developmental or pathogenic processes.

- 45 -

17. The composition of claim 13 as a marker or modulator of developmental disorders, particularly cancer, such a B-cell chronic leukemia.
18. The composition of any one of claims 13-15 as a marker or modulator of
5 gene expression.
19. The composition of claim 18 as a marker or modulator of the expression of a gene, which is at least partially complementary to said nucleic acid molecule.
- 10 20. A method of identifying microRNA molecules or precursor molecules thereof comprising ligating 5'- and 3'-adapter molecules to the ends of a size-fractionated RNA population, reverse transcribing said adapter-containing RNA population and characterizing the reverse transcription
15 products.

Fig. 1 A




Fig. 1 B




Fig. 2




Fig. 3




Fig. 4




Fig. 5







Fig. 5 (cont.)

brain
rbmbcx cb ht lg lv co si pc sp kd sm st H



brain
rbmbcx cb ht lg lv co si pc sp kd sm st H




— miR-L


— miR-S

— tRNAs

brain
rbmbcx cb ht lg lv co si pc sp kd sm st H



brain
rbmbcx cb ht lg lv co si pc sp kd sm st H



— miR-L

— miR-S

Fig. 5 (cont.)




Fig. 5 (cont.)




Fig. 6

A

C. elegans lin-4
D. melanogaster miR-125
M. musculus/*H. sapiens* miR-125b
M. musculus/*H. sapiens* miR-125a

UCCCUGAGACCUC--AAG-UGUGA
 UCCCUGAGACCCU--AACUUGUGA
 UCCCUGAGACCCU--AACUUGUGA
 UCCCUGAGACCCUUAACCUGUGA

B




Fig. 7

name	sequence	structure
let-7a-1	UGAGGUAGUAGGUUGUAUAGUU	UG U U UAGG ACA C CAC UGGA GAGGUAGGUUGUAUAGUU GUC CCA C GUG AUCCU UUCUGUCAUACAUAUCAA UAG GGU A CA - - - - - A - - C
let-7a-2	UGAGGUAGUAGGUUGUAUAGUU	UU G U UAGAAUUAUAC AA AGG GAG UAG AGGUUGUAUAGUU AUC G UCC UUC AUC UCCGACAUGUCAU UAG G U- G C - - - - - AG
let-7a-3	UGAGGUAGUAGGUUGUAUAGUU	U GGG GAGGUAGGUUGUAUAGUU U UCC UUCUGUCAUACAUAUCAA GUCCCG C U UAGGGUAUC U
let-7b	UGAGGUAGUAGGUUGUGUGGUU	GG U - - A - - - - - UG CGGG GAGGUAGGUUGUGUGGUU UC GGCAG \ GUCCC UUCGCAUCCAUAUCAA AG CCCGUU A - - - - - U AAGGCUC GU
let-7c	UGAGGUAGUAGGUUGUAUAGUU	A UU G U UA G UA AC GC UCCGGG GAG UAG AGGUUGUAUAGUU GA U C \ CG AGGUUC UUC AUC UCCAUAUCAA UU A G C - CU G U - - G GG UC
let-7d	AGAGGUAGUAGGUUGCAUAGU	A C UUA - - - - - GG CCUAGGA GAGGUAGGUUG AUAGUU GGCAG \ GGAUUCU UUCGUCGUCCAGC UAUAUCAA CCCGUU A - - - - - A UGGAGGAACA UU
let-7e	UGAGGUAGGAGGUUGUAUAGU	C CU G U GGA - - - - - A CC GGG GAG UAGGAGGUUGUAUAGU GA GG C GG CCC UUC AUCCUCCGCAUAUCAA CU CC A A CU G - - AGAGGAA C

Fig. 7 (cont.)

let-7f-1	UGAGGUAGUAGAUUGUAUAGUU	AGU UCAG GAGGUAGUAGAUUGUAUAGUU AGUC UUCGUAUUAUUAUUAUUAUUA CC- GAGGACUUG ----- UG GGGUAG UCCCAUU A UU
let-7f-2	UGAGGUAGUAGAUUGUAUAGUU	U CUGUGGGA GAGGUAGUAGAUUGUAUAGUU GGCACCCU UUCUGUACUUGACAUUAUCAA ----- UCAU UUAGGG A C ACCC
let-7g	UGAGGUAGUAGUUUGUACAGUA	A U A CC GGC GAGGUAGU GUUUGUACAGUU GG CCG UUCGUAUUAUUAUUAUUAUUA A - - C ----- UGAGG A- A A C C UACC C AUGG C C GG - C
let-7h	UGAGGUAGUAGUGUGUACAGUU	
let-7i	UGAGGUAGUAGUUUGUGCU	U CUGGC GAGGUAGUAGUUUGUGCU GAUCG UUCGUAUUAUUAUUAUUAUUA - U ----- U UGAGGUG - UGUG GG CCGGU UC GCCCG A UUAC
mir-1	UGGAAUGUAAAGAGUAUGGAG	A UUUGAGA UUC GCC GUUCCAUUGCUUC UUGCAUUC AUA GUU GAG CGG CGAGGUAGUAG AUUGUAAG UAU CGA U - UCUAAG A ----- AUA A G A ACU
mir-1b	UGGAAUGUAAAGAGUAUGUAA	A UGGGA ACAUACUUCUUAUUAUUAUUAUUA ACUCU UGUUAGUAGAGAAUGUA A ----- GC CCAUA GGUUAU AUC C CGA GU AC UGG C

AL449263.5

Fig. 7 (cont.)

miR-1c	UGGAAUGUAAAGAGUAUGUAC	
miR-1d	UGGAAUGUAAAGAGUAUGUAAU	C GC UGAACC GCUUGGGA ACUAUACUUCUUUAU CCAUA U CGGACUUU UGUUGAAGAAUGUA GGUU G A A- CGAAUC
miR-2a-1	UAUCACAGCCAGCUUUGAUGAGC	- - - A AUUUC UU GCUGGGCUC UCAAAG UGUUGUGA AUGC CGC \ CGAUUCGAG AGUUUC ACCGACACU UACG GCG U U G A ----- CG
miR-2a-2	UAUCACAGCCAGCUUUGAUGAGC	A C --- GAUAC AUCU AGC UCAUCAAG UGUUGUGUAUUG \ UAGG UCG AGUAGUUU ACCGACACUAUAC C A - CG GCAAC
miR-2b-1	UAUCACAGCCAGCUUUGAUGAGC	U UG - - - A C----- U CU CAAC UCUUCAAG UGGC GUGA AUGUUG C GG GUUG AGGAGUUUC ACCG CACU UUAUAC A C CG G A AUACU A
miR-2b-2	UAUCACAGCCAGCUUUGAUGAGC	A A UUU-- CUU UUGUGUC UUCUCAAAG UGUUGUGA AUG GC U AGCGCAG GAGGAGUUUC ACCGACACU UAC CG U C G A UUAUC UAU
miR-3	UCACUGGGCAAAGUGUGUCUCA	C C G U UUCA GAUC UGGGAUGCAU UUGU CAGU AUGU \ CUAG ACUCUGUGU AACG GUCA UACA A A A G C CUCU

Fig. 7 (cont.)

miR-4	AUAAAGCUAGACAACCAUUGA	U U U C C C G G U U UUGCAU AGUUC UGU GUC AGC UUA UGAU \ GGUGUUG UUGAAG ACCA CAG UCG AAU ACUGG U C U U A A A -- CC
miR-5	AAAGGAACGAUCGUUGUGAUAUG	UA--- C AGUUGU GC AAAGGAA GAUCGUUGUGAUAUG \ CG UUUCCUU UUAGUGACACUAUAC U CAAUA - AAUCCU
miR-6-1	UAUCACAGUGGCUGUUCUUUUU	A- C AG UAAUA UUUA UGUAGAGGGAUAUUGCUGUG UGUA U \ AAAU AUGUUUUUCUUGCGGUGACAC AAUA A U CC U CU UACCA
miR-6-2	UAUCACAGUGGCUGUUCUUUUU	C UU UG C U - G UAACC AAGGGAAC C CUG UGAUAUA UA UU A GUUGG UUUUCUUG G GAC ACUAUAU AU AA A U UC GU C C A
miR-6-3	UAUCACAGUGGCUGUUCUUUUU	A A U AAAC CAAA AGAAGGGAACGGUUGCUG UGAUGUAG UUG \ GUUU UUUUUUCUUGCUGGUGAC ACUAUAU AAC U G - U ACUC
miR-7	UGGAAGACUAAGUGAUUUUUGUUGU	U U U U -- UGGUC GAGUGCAU CCGUA GGAAGAC AG GAUUU UGUUGUU \ UUUACGUG GGCAU UCUUCUG UC CUAAA ACAAUAA U C - U C UA UGGUU
miR-8	UAAUACUGUCAGGUAAAAGAUGUC	CUGUUC - G C UCCUUU AAGGACAU ACAUCUU ACC GGCAG AUUAGA \ UUCCUGUG UGUAGAA UGG CUGUC UAAUCU U CCUGC- A A A CAAUAU

Fig. 7 (cont.)

miR-14	UCAGUCUUUUUCUCUCUCCUA	<p> <u>C C C C</u> GCUU \ UGUGGAG GAGA GGGGACU ACUGU \ AUAUCCUC CUCU UUUUCUGA UGAUA A <u>U U C</u> AAUU </p>
miR-15a	UAGCAGCACAUAAUGGUUUUGUG	<p> GAGUAAAGUA GA U CCUUG GCAGCACA AUGGUUUUGU UUU \ GGAAC CGUCGUGU UACCGGACGU AAA G AUA AAAACUC UA GG A </p>
miR-15b	UAGCAGCACAUCAUGGUUUACA	<p> <u>U C C C</u> A A ACA CUG AGCAGCA AU AUGGUUU CAU CU \ GAU UCGUCGU UA UACUAAAG GUA GA G <u>C U U C</u> - ACU </p>
miR-16	UAGCAGCACGUAAAUAUUGGCG	<p> AG C - A CGUUA UCUA GUCAGC UGC UUAGCAGCAC GU AAUAUUGG AGAU \ CAGUUG AUG AGUCGUCGUG CA UUAUGACC UCUA A GA A U A ----- UUA </p>
miR-16	only different precursor	<p> UC CU UA C AG AAU GU CACU AGCAGCAG AAUAUUGG GU UGA A CA GUGA UCGUCGUGU UUAUAACC CA AUU U GU UU CA A A... AUA </p>
miR-17	ACUGCAGUGAAGGCACUUGU	<p> GA CA- A G G - AUA GUCA AUAUUGU AAGUGCUU CA UGCAG UAG UG \ CAGU UAUUACG UUCACGGA GU ACGUC AUC AC U GG AUG A G - U GUG </p>
miR-18	UAAGGUGCAUCUAGUGCAGUA	<p> CU U C U A UGAA AG UGUU AAGG GCAU UAG GCAG UAG GU A ACGG UUCG CGUG AUC CGUC AUC CG U UC U A C - UA-- AU </p>

Fig. 7 (cont.)

miR-23b	AUCACAUGCCAGGGAUUAACCAC	<p>C U -- C GUGACU GG UGC UGG GUUCCUGGCA UG UGAUUU U CC ACG ACC UAGGACCGU AC ACUAAA G A C AU U - AUAGA</p>
miR-24-1	UGGCUCAGUUCAGCAGGAACAG	<p>G G A UA UCUCAU CUCC GU CCU CUGAGCUGA UCAGU GAGG CA GGA GACUUGACU GGUCA U A A C C- CACAUU</p>
miR-24-2	UGGCUCAGUUCAGCAGGAACAG	<p>CC CG CU- AA-- UU CUCUG UCC UGC ACUGAGCUG ACACAG GGGAC AGG ACG UGACUCGGU UGUGUU G A- -- ACU CACA UG</p>
miR-25	CAUUGCACUUGUCUCGGUCUGA	<p>A AG G UU G UG ACG GGCC GUGUUG AGGC GAGAC G GCAAU CUGG C CCGG CGUGAC UCUG CUCUG C GGUUA GGUC U C AG G UU A CG CCG</p>
miR-26a	UUCRAGUAUCCAGGAUAGGCU	<p>- G U U GCAG AGGCC GUG CCUCGU CAAGUAA CCAGGAUAGGCUU G UCCGG CGC GGGGCA GUUCAUU GGUUCUAUCCGGUA U G A C - ACCC</p>
miR-26b	UUCAAGUAUUCAGGAUAGGUU	<p>GA - U UC UGUG CCGG CCC AGU CAAGUAAU AGGAUAGGUU GGCC GGG UCG GUUCAUUA UCUGUCCGAC C AG C - CC CUGU</p>
miR-27a	UUCACAGUGGCUAAGUUCGCGU	<p>A A A U G UCCAC CUG GG GC GGGCUUAGCUGCU GUGAGCA GG GAC CC CG CUUGAAUCCGGUGA CACUUGU CU A C C C G GRACC</p>

Fig. 7 (cont.)

miR-27b	UUCACAGUGGCUAAGUUCUG	AUUG UGAU U AGGUCAGAGCUUAGCUG GUGAACAG UGG \ UCCACGUCUUGAAUCGGU CACUUGUU GCC U GA-- UC-- U
miR-28	AAGGAGCUCACAGUCUAUUGAG	C A U ----- CC GGU CUUGCCCCUC AGGAGCUCACAGUCUA UG AGUUA U UCA GGACGGGAG UCCUCGAGUGUUAGAU AC UCAGU U C G C CCUU CU
miR-29a	CUAGCACCAUCUGAAAUCCGGUU	UUU C UCAAU AUGACUGAUUUC UGGUGUU AGAG \ UAUUGGCUAAAG ACCACGA UCUU A UCU - UUAUU
miR-29b	UAGCACCAUUUGAAAUCCAGUGUU	A U GU UUAUU AGGA GCUGGUUUA AUGGUG UUAGAU \ UCUU UGACUAAAGU UACCAC GAUCUG A G U -- UUAGUG
miR-29c	UAGCACCAUUUGAAAUCCGGUUA	
miR-30a-s	UGUAAACAUCUCCGACUGGAAGC	A UC ----- A GCG CUGUAAACAUCUCC GACUGGAAGCU GUG A CGU GACGUUUUGUAGG CUGACUUUCGG CAC G C -- GUAAA C
miR-30a-as	CUUUCAGUCGGGAUGUUUGCAGC	A UC ----- A GCG CUGUAAACAUCUCC GACUGGAAGCU GUG A CGU GACGUUUUGUAGG CUGACUUUCGG CAC G C -- GUAGA C

Fig. 7 (cont.)

mir-30b	UGUAAACAUCUACACUCAGC	<p> <u>U</u> - UCAUA AUGUAAACAUC <u>ACA</u> CUCAGCUG C UGCAUUUGUAGG UGU GGGUCGGU A - A UGCGU </p>
mir-30c	UGUAAACAUCUACACUCAGC	<p> UACU <u>U</u> ACA GUGGAA AGA <u>GUAACA</u> <u>CCU</u> CUCUCAGCU A UCU CAUUUGU GGA GAGGGUCGA G UUCU C A-- AAGAAU human </p>
mir-30d	UGUAAACAUCUACACUCAGC	<p> U U CCC GUAAGA GU GU GUAAACAUC GACUGGAAGCU C CA CG CGUUUGUAG CUGACUUUCGA A U U A-- AUCGAC chr8 human </p>
mir-31	GGCAAGAUGCUGGCAUAGCUG	<p> GA G C U- GAA GGAGAG <u>GGCAA</u> <u>AUG</u> <u>UGGCAUAGC</u> GUU C CCUUUC CCGUU UAC ACCGUUUCG CAA U UA A A UC GGG </p>
mir-32	UAUUGCACAUAUAAGUUGC	<p> U - UU C GGAGAUUUGCACAUAUAAGUUGCAU G GU A CUUUUAUAUGUGUGUG UGAUUUAACGUA C CG C - A UC G </p>
mir-33	GUGCAUUGUAGUUGCAUUG	<p> A UU UUCU UG CUGUGGUGCAUUGU G GCAUUGCAUG GG A GACACUACGUGACA C UGUAAACGUAC CC G C UU ---- AU </p>
mir-99a	ACCCGUAGAUCCGAUCUUGU	<p> A UC U G AAG CAUA ACCCGUAGA CGA CUUUGUG UG U GUGU UGGGUUUCU GCU GAACGC GC G C UU C - CAG </p>

Fig. 7 (cont.)

miR-99b	CACCCGUAGAACCGACCUUGCG	<p>CC AC C ---- C</p> <p>GGCAC ACCCGUAGA CGA CU UGCGG GG \</p> <p>CUGUG UGGGUGUCU GCU GA ACGCC CU C</p> <p>CC GU C ACAC G U</p>
miR-101	UACAGUACUGUGAUACUGA	<p>A GUCCA</p> <p>UCAGUUAUCACAGUGCUG UGCU U</p> <p>AGUCAUAGUGUCAUGAC AUGG U</p> <p>- AAAUC</p>
miR-122a	UGGAGUGUGACAAUGGUGUUUGU	<p>GG C UGUCC</p> <p>AGCUGU AGUGUGA AAUGGUGUUUG A</p> <p>UCGAUA UCACACU UUACCGCAAC A</p> <p>AA A UAUA</p> <p>woodchuck</p>
miR-122b	UGGAGUGUGACAAUGGUGUUUGA	
miR-122a,b	UGGAGUGUGACAAUGGUGUUUG	
miR-123	CAUUAUUACUUUUGGUACGCG	<p>A A U CGCUG C</p> <p>UGAC GC CAUUAUUACUU UGGUACG UGA A</p> <p>ACUG CG GUAAUUAUAGAG GCCAUGC ACU C</p> <p>G C U UCAA- U</p>
miR-124a*	UUAAGGCACGCGGUGAAUGCCA	<p>- C A GA UAAUG</p> <p>CUCU G GUGUUCAC GCG CCUUGAUU U</p> <p>GAGA C CGUAAUG CGC GGAAUUA C</p> <p>A - G AC CAUUA</p>

Fig. 7 (cont.)

miR-124b	UUAAGGCACGCGGGUGAAUGC	CC A GA UAAUG CUCU GUGUUCAC GCG CCUUGAUU \ GAGA CGUAAGUG CGC GGAAUUA U AC G AC CAUAC AC021518
miR-125a	UCCUGAGAGACCCUUUAACCUGUG potential lin-4 ortholog	C C UA ---- A CUGGGU CCUGAGA CCUU ACCUGUGA GG C GGUCCG GGGUUCU GGAG UGGACACU CC G A U -- GGA U
miR-125b	UCCUGAGAGACCCUAACUUGUGA potential lin-4 ortholog	UC C A GG- U GCCUAG CCUGAGA CCU ACUUGUGA UAU U CGGAUC GGGUUCU GGA UGAACACU AUG U CA U C ACA A
miR-126	UCGUACCGUGAGUAUAUAUGC	A U CGCUG C GC CAUUAUUACUU UGGUACG UGA A CG GUAAUAUAUGAG GCCAUGC ACU C C U UCAA- U
miR-127	UCGGAUCCGUCUGAGCUUGGCU	A U G G C -- AG CC GCC GCU AAGCUCAGA GG UCUGAU UC \ GG UGG CGG UUCGAGUCU CC AGGCUA AG A C U - G U CU AA
miR-128	UCACAGUGAACCGGUCUCUUUU	UUC UAG CU U GUUGGA GGGGCCG CACUGU GAGAGGU U CGACUU CUCUGGC GUGACA CUCUUUA A UUU CAA -- C
miR-129	CUUUUUUCGGUCUGGGCUUGC	- C CU G UUCU C GGAU CUUUUUG GGU GGGCUU CUG CU A UCUA GAAAAAC CCA CCCGAA GAC GA A U C UU G UGAU- C human

Fig. 7 (cont.)

miR-130	CAGUGCAAUGUUAAAAGGCG	<p>- C A GUCUAAG GA GCUCUUU ACAUUGUGCU CU \ G CU CGGGAAA UGUAACGUGA GA G A U C GCCAUGU</p>
miR-131	UAAAGCUAGAUAAACCGAAAGU	<p>G C G U A GUU UUAU UUUGGUUAUCUAGCU UAUGAG GU U CAA AAUG AAGCCAAUAGAUCGA AUACUU UG U A A A C G</p>
miR-132	UAAACAGUCUACAGCCAUGGUCGU	<p>A UUC G- G GGGC ACCGUGGCU GAUUGUUACU UGG \ CCCG UGGUACCGA CUGACA AUGG GCC A C CAU AG A</p>
miR-133	UUGGUCCCCUUCACCCAGCUGU	<p>A AA U A GCCUC GCUA AGCUGGU AA GG ACCAAAUC U CGAU UCGACCA UU CC UGGUUUAG U G AC C C GUAAC</p>
miR-134	UGUGACUGGUUGACCAGAGGGA	<p>GU U A- G GCGU AC AGGGU GUGACUGG UG CCA AGG GC \ UCCCA CACUGAUC AC GGU UCCC UG U AC C CG G ACU- UC</p>
miR-135	UAUGGCUUUUUUAUCCUAUGUGAA	<p>UU UUCUUAU CUAUGGCUUU AUUCCUAUGUGA \ U GGUGCCGAGG UAGGGAUAUACU U U- CGCUCG</p>
miR-136	ACUCCAUUUGUUUUGAUGAUGGA	<p>C UUU UUCU GAGGACUC AUUUG UGAUGAUGGA \ CUUCUGAG UAAAC GCUACUACCU U - UCU CGAA</p>

Fig. 7 (cont.)

miR-137	UAUUGC UUAAGAAUACGCCGUAG	<p>CUUCGGU ACG GUUAUCUUGGGUGG UAAUA CG \</p> <p>GGAGCUG UGC CAUAAGAUAUCGUU AUUGU GC U</p> <p>A G - - U AU</p>
miR-138	AGCUGGUGUUGUGAAUC	<p>-- UCA AC- C CG</p> <p>CAGCU GGUGUUGUGAA GGCCG GAG AG C</p> <p>GUUGG CCACAGCACUU UCGGC UUC UC A</p> <p>GA UA- CCA - CU</p>
miR-139	UCUACAGUGCACGUGUCU	<p>G - U A GUGGC</p> <p>GU UAUUCUA CAG GC CGUGUCUCCAGU \</p> <p>CA AUGAGGU GUC CG GCGCAGAGGUCG U</p> <p>- U C - GAGGC</p> <p>human</p>
miR-140	AGUGGUUUUACCCUAUGGUAG	<p>- A A UU UC</p> <p>CCUG CC GUGGUUUACCCU UGGUAGG ACG A</p> <p>GGAC GG CACCAAGAUGGA ACCAUCU UGU U</p> <p>A - - C -- CG</p>
miR-141	AACACUGUCUGGUAAGAUGG	<p>U -- U AU GAAG</p> <p>GGG CCAUCUU CCAG GCAGUGUUGG GGUU \</p> <p>CCC GGUAGAA GGUC UGUCACAAUC UCGA U</p> <p>- AU - C- AGUA</p>
miR-142s	CAUAAAGUAGAAAGCACUAC	<p>AC- A UAA--- G</p> <p>CCAUAAGAUAAGAGCACUAC CA C</p> <p>GGUAUUUCAUC UUUGUGAUG GU A</p> <p>GUA C UGGGAG C</p>
miR-142as*	UGUAGUGUUUCCUACUUUAUGG	<p>AC- A UAA--- G</p> <p>CCAUAAGAUAAGAGCACUAC CA C</p> <p>GGUAUUUCAUC UUUGUGAUG GU A</p> <p>GUA C UGGGAG C</p>

Fig. 7 (cont.)

new	AUAAGACGAGCAAAAAGCUUGU	<p>G G C G G C AU</p> <p>UGAC GCGAGCUUUU GC CG UUAUAC UG \</p> <p>ACUG UGUUCGAAAA CG GC AAUAUG AC G</p> <p>G A A AG C UC</p> <p>AL049829.4</p>
miR-143	UGAGAUGAAGCACUGUAGCuca UUAGAUGAAGCACUGUAG	<p>G G U - AG</p> <p>CCUGAG UGCAGUGCU CAUCUC GG UC U</p> <p>GGACUC AUGUCACGA GUAGAG CU AG U</p> <p>G A U G GG</p> <p>AC008681.7</p>
miR-144	UACAGUAUAGAUGAUGUACUAG	<p>G A A- GU</p> <p>GGCUGG AUAUCAUC UUAUCUGUA GUUU G</p> <p>CUGAUC UGUAGUAG AUAUGACAU CAGA A</p> <p>A - CA GU</p>
miR-145	GUCCAGUUUUCCAGGAUCCCUU	<p>C UC U C UGGAUG</p> <p>CUCA GG CAGU UU CCAGGAUCCCU \</p> <p>GAGU UC GUCA AA GGUCCUUAGGG C</p> <p>- UU U A UAGAAU</p>
miR-146	UGAGAACUGAAUUCCAUGGGUUU	<p>CU C AUAUC</p> <p>AGCU GAGAACUGAAUU CAUGGGUU A</p> <p>UCGA UUCUUGACUUAA GUGUCCAG A</p> <p>C- A ACUGU</p>
miR-147	GUGUGUGGAAAUAGCUUCUGCC	<p>A- CAA ACA--- GA</p> <p>AAUCUA AGA CAUUUCUGCACAC CCA \</p> <p>UUAGAU UCU GUAAAGGUGUGUG GGU C</p> <p>CG UC- ACCGA AU human</p>
miR-148	UCAGUGCACUACAGAACUUUGU	<p>- A- CC - AGU</p> <p>GAGGCAAAGUUCUG AG CACU GACU CUG \</p> <p>CUCUGUUUCAAGAC UC GUGA CUGA GAU A</p> <p>A AC -- A AGU human</p>

Fig. 7 (cont.)

miR-149	UCUGGCUCGUGUCUUCACUCC	<p> <u>G</u> <u>C</u> <u>G</u> <u>A</u> <u>GUG</u> <u>G</u> GGCUCUG CUC GU UCUUC CUCCC UUU U UCGGGC GAG CA GGAGG GAGG GAG C G A G - AG- C </p>
miR-150	UCUCCCAACCCUUGUACCAGUGU	<p> <u>AC</u> <u>U</u> <u>UG-</u> <u>UG</u> CCUGUCUCCCA CCU GUACCA G CUG \ GGGAUAGGGGU GGA CAUGGUC GAC C CC - CCA UC </p>
miR-151	CUAGACUGAGGCCUUCUUGAGGU	<p> C CA UGUCU CCUG CCUCGAGGAGCU CAGUCUAGUA \ GGAC GGAGUCCCGG GUCAGAUCAU C A A- CCCUC </p>
miR-152	UCAGUGCAUGACAGAACUUGG	<p> G A CC CGG C CCGGCCUAGGUUCUGU AU CACU GACU GCU U GGCCCGGGUUCAGACA UA GUGA CUGA CGA G G C -- -- G </p>
miR-153	UUGCAUAGUCACAAAAGUGA	<p> GU A- AAU CAGUG UCAUUUUUGUGAU UGCAGCU GU \ GUUAC AGUGAAACACUG ACGUUGA CG A U AU CC AGU </p>
miR-154	UAGGUUAUCCGUGUUGCCUUCG	<p> U - CCU-- UUU GAAGAUAGGUUA CCGUGU UG UCGC \ UUUUUAUCCAGU GGCACA AC AGUG A U U UAAGC UUU </p>
miR-155 [BIC-RNA]	UUAAUGCUAAUUGUGAUAGGGG	<p> U U A UUGGCC CUGUUAUAGCUAAU G G UAGGGGU GACAAUACGAUUG U C AUCCUCAG U - C - UCAGUC </p>

Fig. 7 (cont.)

name	sequence	structure
miR-C1	AACAUAUCAAACGUCUGCGGUGAGU	<pre> U A U CU A GGAUUA CCA GG ACA UCAACG GUCGGUG GUUU \ GGU CC UGU AGUUGC CAGCCAG CAAA A U A C -- - AAAACAAA </pre>
miR-C2	UUUGGCAAUGGUAGAACUCACA	<pre> UU UGG UCA UAAGGU ACCAU UUGGCAA UAGAAC CACCGG A UGGUA AACCGUU AUCUUG GUGGCC A UC CAG --- CAGGGU </pre>
miR-C3	UAUGGCACUGGUAGAAUUCACUG	<pre> G AC-- GA -- AC CUGU UAUGGC DGGUA AUUCACUG UGA A GACA AUACCG GCCAU UAAGUGAC ACU G A GGAA -- UG CU </pre>
miR-C4	CUUUUUGCGGUCUGGGCUUGUU	<pre> - C CU G UUUU C UGGAU CUUUUG GGU GGGCUU CUG CU G AUCUA GAAAAAC CCA CCCGAA GAC GA A U C UU G UGAU C </pre>
miR-C5	UGGACGGAGAACUGAUAAGGU	<pre> U C C AG - UG CCU UCCUUAUCA UUUUCC CCAGC UUUG A GGA GGGAAUAGU AAGAGG GGUUG GAU C U C CA U CU </pre>
miR-C6	UGGAGAGAAAAGGCAGUUC	<pre> A G AU UC AGGAUUGGAG GAAAG CAGUUCUUG GG C UUCCUGGUCUC CUUUC GUGGGGGAC CC C - G -- UC </pre>

Fig 7 (cont.)

name	sequence	structure
miR-C7	CAAAGAAUUCUCCUUUUGGGCUU	<pre> U UU UCUCAU ACUUUCCAAAGAAUUC CCUU GGGCUU U UGAAGGGUUUUUUAAG GGAA CCCGAA U U U- UUUUAU </pre>
miR-C8	UCGUGUCUUGUGUUGCAGCCGG	<pre> A A C CGCUGC UC GGCU CAACACAGGAC CGGG U GG CCGA GUUGUGUUCUG GCUC C - C U CCCAGU </pre>
miR-C9	UAACACUGUCUGGUAACGAUGU	<pre> - C C UU UUG GGGCAUC UUAACGGACAGUG UGGA UC \ CUUGUAG AAUGGUCUGUCAC AUCU AG G C A C- UUC </pre>
miR-C10	CAUCCCUUGCAUGGUGGAGGGU	<pre> CA UC GU UGAGCUC UCU CA CCUUGCAUG GGAGGG U AGG GU GGGACGUAC CCUCCC C AC UU AC CAAAAGU </pre>
miR-C11	GUGCCUACUGAGCUGACAUCAGU	<pre> G G A UA UCUCAU CUCC GU CCU CUGAGCUGA UCAGU \ GAGG CA GGA GACUUGACU GGUCA U A A C C- CACACU </pre>
miR-C12	UGAUAUGUUUGAUUAUUAGGU	<pre> U- UA--- UU CUGUG GAUAUGUUUGAUUAU \ GACAU UUAUACGAACUAUAU CUAU A CC UCAAC UU </pre>

Fig. 7 (cont.)

name	sequence	structure
miR-C13	CAACGGAUCCCAAAAGCAGCU	<pre> C C A A U U - C AGGGG AACGGAUCC AA GCAGCUG GU CU C UCGUCC UUGCUUAGG UU CGUCGAC UA GA A C - CA CU C G </pre>
miR-C14	CUGACCUAUGAAUUGACA	<pre> C - A UGCUCUC UGACCUAUG AAUUG CAGCCAG G ACUGGAUAC UAAAC GUCGGUC U - C C UCCCCUC </pre>
miR-C15	UACCACAGGGUAGAACACACGGA	<pre> - G A U U UC UCCUG CCG UGGUUUACCCU UGGUAGG ACG A AGGAC GGC ACCAAGAUGGGA ACCAUCU UGU U A - C -- CG </pre>
miR-C16	AACUGGCCUACAAAGUCCCG	<pre> A U C A A AGU GAG GCUGGG CUUUG GGGC AG UGAG G CUC UGACCC GAAAC UCCG UC ACUU U C U A G A GAC </pre>
miR-C17	UGUAAACAGCAACUCCAUGUGGA	<pre> U A G - - U AUCGGG GUAACAGCA CUCCA UGGA CUG G UAGUCU CAUUGUCGU GAGGUG ACCU GGC C U C - UA U </pre>
miR-C18	UAGCAGCACAGAAAUUUGGC	<pre> U A- UG GAA AGCAGCACAG AAUAUUGGA GG G UCGUCGUGUC UUAUAACCGU CU U GG -- GAG </pre>

Fig 7 (cont.)

name	sequence	structure
miR-C19	UAGGUAGUUUCAUGUUGUUGG	<pre> A A C GGCUGGG GUGAAUU GGU GUUU AUGUUGUUG U CACUUG CCA CAA UACAACAAC U C C C U ACAAGUCU </pre>
miR-C20	UUCACCAACCUUCUCCACCCAGC	<pre> C A A CA GA - A GGCUGUGC GGU GAGAGGG GUGG GGU AAG G CCGGUACG CCCA CUCUUC CACU CCA UUC C A C AC UC C U </pre>
miR-C21	GGUCCAGAGGGGAGAUAGG	<pre> G - C G U UUCCUG UCAUU G UC A AGGGAGA AGG U AGUAA U AG U UCUCUUCU UCC G A A A A - UUUUUA </pre>
miR-C22	CCCAGUGUUCAGACUACCUGUU	<pre> AAC U C U G--- G GCC CCAGUGU CAGACUAC UGU CA GAG \ CGG GGUUACA GUCUGAUG ACA GU CUC C AUU C - U GUAA U </pre>
miR-C23	UAAUACUGCCUGGUAUGAUGAC	<pre> GGC - C UAGUG GCCGU CAUC UUACUGGGCAG AUUGGA U CGGCA GUAG AAUGGUCCGUC UAAUCU C --- U A CUAGU </pre>
miR-C24	UACUCAGUAAGGCAUUGUUCU	<pre> U U UUC A UACCUAC CAG AAGGCAUUGUUC UAU U AUGGGAUG GUC UUCGUGACAAAG AUA U U U UAA A </pre>

Fig. 7 (cont.)

name	sequence	structure
miR-C25	AGAGGUAUAGCGCAUGGGAAGA	<pre> U A- UG C GUUCC UUUUCCUAUGC UAUACUUCUU UGGAU \ CGAGG AGAAGG<u>GUACG</u> AUAUGGAGAA AUCUG U U CG -- G </pre>
miR-C26	UGAAAUGUUUAGGACCA <u>CUAG</u>	<pre> C U G A C U GGUC AGUGGUUCU GACA UUCA CAGUU UG \ CCAG UCACCAGGA UUGU AAGU GUUAA AC A A U A - C G </pre>
miR-C27	UUCCCUUUGUCAUCCUAUGCCUG	<pre> U A U GAGAAUA UGGAC UCCCUUUGUC UCCUA GCCU \ ACUUG AGGAAACGG AGGGU CGGA U C A - GGAAGUA </pre>
miR-C28	UCCUUCAUUCCACCGGAGUCUG	<pre> UC C UCUUA CUCUUG CUUCAUCCAC GGAGUCUG U GAGGAC GAAGUGAGGUG CUUUGAGAC G UC A CAACC </pre>
miR-C29	GUGAAAUGUUUAGGACCA <u>CUAGA</u>	<pre> U C U G A C U GCC GGUC AGUGGUUCU GACA UUCA CAGUU UG \ CGG CCAG UCACCAGGA UUGU AAGU GUUAA AC A C A U A - C G </pre>
miR-C30	UGGAAUGUAAGGAAGUGUGUGG	<pre> - C U AUAUC CCAGG CCACAUGCUUUUAUUAU C CAUAG \ GGUUU GGUGUGUAAGGAAGUA G GUAUC U U A - ACGAC </pre>

Fig 7 (cont.)

name	sequence	structure
miR-C31	UACAGUAGUCUGCACAUGGUU	<pre> AUC U C ----- G GCC CCAGUGU CAGACUAC UGU UCAG A CGG GGUUACA GUCUGAUG ACA GGUC G AUU C - UGUACAG G </pre>
miR-C32	CCUGUAGAACCGAAUUUGUGU a miR-10 variant	<pre> A G C UG- AC UADAU CCCU UAGAA CGAAUUUGU GU C AUAUA GGGG AUCUU GCUUAGACAC UA C A - A UGA CA </pre>
miR-C33	AACCCGUAGAUCCGAACUUGUGA A a miR-99a variant	<pre> A C C A C AU CACA ACC GUAGAU CGA CUUGUG UG U GUGU UGG UAUCUG GUU GAACAC AC C A A U C - GU </pre>
miR-C34	GCUUCUCCUGGCUCUCCUCCUC	<pre> C U UUG - GGAG AAGG AGGGG GAGGGG CGGGAGGAGC CGGGC G UUCU UCUCU CUCCUC GUCCUCUUCG GUUCG C - - UCG C GCGU </pre>

Fig. 7 (cont)

name	human	C. elegans	mouse							Drosophila	fugu fish	zebrafish
			liver	small intes	colon	cerebellum	cortex	midbrain	heart	spleen		
let-7a-1	AC007924 chr9 AC087784 chr 17 identical precursor		num. hits in trace data, 3 families of similar precursors		found		nearly identical precursor	found				
let-7a-2	AF001359 chr11						nearly identical precursor					
let-7a-3	AL049053 chr22	AP274345 chrX with diff. precursor								AS003659 diff. precursor		
let-7b	AL049853 chr22		nearly identical precursor			nearly ident precursor trace#4311003		found	EST AF491799.1 spleen = cerebellum (mammary)		with slightly diff precursor	
let-7c	AP001667 chr21		identical and diff. precursors			num. genomic hits, ident precursor, diff precursor -> EST AF614897	numerous genomic hits	found				
let-7d	AC007924-3 chr9 AC087784 chr17 identical				found	trace#03507042 nearly ident prec	trace#0358704 2 nearly ident prec	found	found			
let-7e	AC018755 chr19							found		FOUND		
let-7f-1	AC007924 chr9 AC007704 chr17					ident precursor genomic DNA		found	found			
let-7f-2	AL592046 chrX					ident. precursor in mnttrace 18713911						
let-7g	precursor ident. to mouse in AC092045.2 chr3					genomic hits, no EST		found				
let-7h							found in cortex, no db hit					

[illegible]

Fig. 7 (cont.)

miR-5																	2R, AE003795				
miR-6-1																	2R, AE003795				
miR-6-2																	2R, AE003799				
miR-6-3																	2R, AE003799				
miR-7	AC003791 chr19 diff-precursor: EST AF371391 again different																2R, AE003791				
miR-8																	2R, AE003805				
miR-9	AC005316 chr15 AC026701 chr5 each with diff. precursor																3L, AE003516	2diff precurs scaffold- 3868 and 2417			
miR-10	AF207967 chr11 (Hox B4/B5)																AE001574				
miR-11																	3R, AE003735				
miR-12																	X, AE003499				
miR-13a																	3R, AE003708				

not cloned, but mouse EST predicts precursor similar to human

AF155142.1 chr19
diff
prec, sligh. diff
prec.s in trace
hits

found

not found, but AC011194 chr.11 predicts diff. precursor

Fig. 7 (cont.)

[illegible]

[illegible]

Fig. 7 (cont.)

[illegible]

[illegible]

Fig. 7 (cont.)

miR-124a*	nearly ident. precursor in chr8[AC021518] chr20[AL096828]	found in 272504.1 chr14 intron,diff precursor	found		most abundant in cereb., genomic hits (trace#21097008, 11737241) found, but no db hit	found	found	slightly diff precursor AC009251 chr2L		
miR-124b	AC021518 chr8, nearly ident chr20 AL096828.29									
miR-125a	ident precu in AC018755.3 chr 19				found					
miR-125b	AP001359.4 Chr11 AP001667.1 Chr21(chr21 like mouse)				trace#8398570 5	found with A22U	found in AC006590.1 1 with diff fold	Scaffold_ 2358		
miR-126					mmtrace#3521597 and more		found	with diff precursc affold_32 95		
miR-127	human AL117190.6 chr.14 same precurs as in mouse				hit in trace#79514537					
miR-128	ident in AC016742.10 chr 2;diff prec in AC016943.7 chr.3				genomic hit trace#51670230	found	found	Scaffold_ 828,diff- prec		
miR-129	human AC018662.3 chr7				found, but no db hit					
miR-130					mmtrace 68479278				with diff fold AC091299.2	
miR-131	AC005317.2 chr 15 sligh.diff precursor,but AC026701.6 chr 5 ident				several trace hits,mouse AF155142	found				
miR-132	AL137038.5 chr17 prec sligh.diff from mouse				trace hit#86984641					

Fig. 7 (cont.)

miR-133	AL391221.15 chr6 diff. Precursor (ident to rat L33722.1)							found, trace# 62407955	found	AC093440.1 diff. Precursor	Scaffold_ 1049; prec u nearly like mouse	
miR-134	AL132709.5 chr14 similar precursor							trace#646201 1				
miR-135	AC092045.2 chr3 AC018659.35 chr12 (ident or simil to mouse)							trace#7149523 5, EST#F780995 1(hdm, sple en) (=chr3 huma n)	found		Scaffold_ 2125 with similar precurs	
miR-136	AL117190.6 chr14 ident to mouse							trace#8607175 3				
miR-137	AC027691.1 chr1 , ident to mouse, nearly ident fish							trace#8977454 3, EST (hypothenal) A18 52436.1, ident .			Scaffold_ 18244 nearly ident to mouse/man	
miR-138	AC006058.1 chr3 precursor diff							mouse EST BB528620.2				
miR-139	AP001065.2 chr11							found, but no mouse hit				
miR-140	AC026468.8 chr.16, precursor r nearly ident,					several trace hits; trace#1053 0393						
miR-141	AC005512.12 chr12, precursor slight diff					AC002397 chr6			found			
miR-142s	AC004687.1 chr17 BCL3/myc translocation locus, like mouse					found						
miR-142as*						several EST A1153235			found			

Fig. 7 (cont.)

[illegible]

Fig. 7 (cont.)

name	human	mouse						Drosophila	fugu fish	zebrafish
		spleen	eye	kidney	testes	lung	thymus			
miR-C1	with different precursors in chr9 AL58075.11, chr1 AL136321.5		mouse trace #76647842			found			scaffold_1819	
miR-C2	chr7 AC084864.2 similar precursor		mouse trace #88841093						scaffold_967	AL590150.2
miR-C3	chr7 AC084864.2 ident. precursor		trace #86029980						scaffold_967	AL590150.2
miR-C4	similar precurs. in chr7 AC018662.3		trace #13885686		found					
miR-C5	chr15 AC069082.9		trace #87318220					found	scaffold_3671	
miR-C6	chr22 AC005664.2 ident. precursor		chr16 AC012526.32							
miR-C7	chr1 AL512443.7 similar prec.		trace #86694995							
miR-C8				found, trace #51673384						
miR-C9				found, trace #78964803					scaffold_2210, diff. precursor	
miR-C10	chrX AF222686.1 nearly ident. precursor			found, trace #61928192						
miR-C11	chr9 XM_098943.1 has C170; prec. nearly identical to mouse			found, cDNA AI286629.1, has C170						
miR-C12				found, trace#71 760450					scaffold_2294	
miR-C13		found		found, trace #88722637						

Fig. 7 (cont.)

name	human	mouse						Drosophila	fugu fish	zebrafish
		spleen	eye	kidney	testes	lung	thymus			
miR-C14	chr11 AC000159.6			found, but no db hit						
miR-C15	chr16 AC026468.6 nearly ident.precursor			EST B1687377.1, several trace					scaffold_2083	
miR-C16	chr17 AC003101.1, similar precursor			found, trace#95 55103					scaffold_246	
miR-C17	chr11 AC000159.6, chr1 AC103590.2; diff.prec.			found, trace #87796602					scaffold_152	
miR-C18				found, trace #47823768 (close to mir-16)		found				
miR-C19	chr17 AC009789.21 cloned from human cell line only			similar precursor in mouse chr11 AC011194.15					scaffold_18334	
miR-C20	chr1 AL355310.19 cloned from human cell line only									
miR-C21	chr3 AC063952.15 cloned from human cell line only									
miR-C22	chr19 AC007229.1; chr1 AL137157.7 similar precursor; cloned from human cell line only								scaffold_8399	
miR-C23					trace #72257777	found			scaffold_2210	
miR-C24					trace #69879879					
miR-C25					trace #49754566					
miR-C26	AL136001 ident. precursor				trace #11977216					

Fig. 7 (cont.)

name	human	mouse						Drosophila	fugu fish	zebrafish
		spleen	eye	kidney	testes	lung	thymus			
mir-C27	chr9 AL159990.12 identical precursor		trace #91503159						scaffold_725	
mir-C28	XM_036612.4, precursor very similar								scaffold_13664	
mir-C29	chr14 AL136001.6 nearly identical precursor									
mir-C30	chr6 AL391221.15 similar precursor									
mir-C31	chr9 AC006312.8								scaffold_5830	
mir-C32									scaffold_82	
mir-C33									scaffold_15612	
mir-C34							trace# 72109322			

SEQUENCE LISTING

<110> Max-Planck-Gesellschaft zur Förderung der Wissensc

<120> Identification of novel genes encoding for small
temporal RNA

<130> 26250PWO_DR

<140>

<141>

<150> EP 01 123 453.1

<151> 2001-09-28

<150> EP 02 006 712.0

<151> 2002-03-22

<150> EP 02 016 772.2

<151> 2002-07-26

<160> 217

<170> PatentIn Ver. 2.1

<210> 1

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 1

tactatacaa cctactacct caatttgcc

29

<210> 2

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 2

actatgcaac ctactacctc t

21

<210> 3

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 3

actatacaac ctctacctc a

21

<210> 4

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 4

tggtgtttcc gcccgga

19

<210> 5

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 5

tggaatgtaa agaagtatgg ag

22

<210> 6

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 6

gctcctcaaa gctggctgtg ata

23

<210> 7

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 7

tgagacacac tttgcccagt ga

22

<210> 8

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 8

tcaatggttg tctagcttta t

21

<210> 9

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 9

catatcacaa cgatcggtcc ttt

23

<210> 10

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 10

aaaaagaaca gccactgtga ta

22

<210> 11

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 11

tggaagacta gtgattttgt tgt

23

<210> 12

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 12

gacatcttta cctgacagta tta

23

<210> 13

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 13

tcatacagct agataaccaa aga

23

<210> 14
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 14
acaaattcgg atctacaggg t 21

<210> 15
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 15
gcaagaactc agactgtgat g 21

<210> 16
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 16
accagtacct gatgtaatac tca 23

<210> 17
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:

Oligonucleotide

<400> 17

actcgtcaaa atggctgtga ta

22

<210> 18

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 18

taggagagag aaaaagactg a

21

<210> 19

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 19

tagcagcaca taatggtttg t

21

<210> 20

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 20

gccaatatatt acgtgctgct a

21

<210> 21

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 21

tacaagtgcc ttctactgcag ta

22

<210> 22

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 22

tatctgcact agatgcacct ta

22

<210> 23

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 23

tcagttttgc atagatttgc aca

23

<210> 24

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 24

tacctgcact ataagcactt ta

22

<210> 25
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 25
tcaacatcag tctgataagc ta 22

<210> 26
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 26
acagttcttc aactggcagc tt 22

<210> 27
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 27
ggaaatccct ggcaatgtga t 21

<210> 28
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 28
ctgttcoctgc tgaactgagc ca 22

<210> 29
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 29
tcagaccgag acaagtgcaa tg 22

<210> 30
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 30
agcctatcct ggattacttg aa 22

<210> 31
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 31
agcggaaactt agccactgtg aa 22

<210> 32
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 32

ctcaatagac tgtgagctcc tt

22

<210> 33

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 33

aaccgatttc agatgggtgct ag

22

<210> 34

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 34

gctgcaaaca tccgactgaa ag

22

<210> 35

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 35

cagctatgcc agcatcttgc ct

22

<210> 36
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 36
gcaacttagt aatgtgcaat a 21

<210> 37
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 37
tgcaatgcaa ctacaatgca cc 22

<210> 38
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 38
ctccatactt ctttacattc ca 22

<210> 39
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 39
gctgagtgtgta ggatgtttac a 21

<210> 40
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 40
gcttccagtc gaggatgttt aca 23

<210> 41
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 41
cgcaagggtcg gttctacggg tg 22

<210> 42
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 42
tcagttatca cagtactgta 20

<210> 43
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 43

acaaacacca ttgtcacact cca

23

<210> 44

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 44

tggcattcac cgcgtgcctt a

21

<210> 45

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 45

cacaggttaa agggctctcag gga

23

<210> 46

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 46

tcacaagtta gggctctcagg ga

22

<210> 47

<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 47
agccaagctc agacggatcc ga 22

<210> 48
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 48
aaaagagacc ggttcactct ga 22

<210> 49
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 49
gcaagcccag accgaaaaa g 21

<210> 50
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 50

gcccttttaa cattgcactc

20

<210> 51

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 51

actttcgggtt atctagcttt a

21

<210> 52

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 52

acgaccatgg ctgtagactg tta

23

<210> 53

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Combined DNA/RNA Molecule:
Oligonucleotide

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 53

tgagctacag tgcttcactc ca

22

<210> 54

<211> 18

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 54
uuuaaccgcg aattccag 18

<210> 55
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 55
acggaattcc tcactaaa 18

<210> 56
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 56
cacaggttaa agggctctcag gga 23

<210> 57
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 57
cagccaacgg aattcctcac taaa 24

<210> 58
<211> 22
<212> RNA
<213> D. melanogaster

<400> 58
uggaauguaa agaaguaugg ag 22

<210> 59
<211> 23
<212> RNA
<213> D. melanogaster

<400> 59
uaucaacagcc agcuuugaug agc 23

<210> 60
<211> 23
<212> RNA
<213> D. melanogaster

<400> 60
uaucaacagcc agcuuugagg agc 23

<210> 61
<211> 22
<212> RNA
<213> D. melanogaster

<400> 61
ucacugggca aagugugucu ca 22

<210> 62
<211> 21
<212> RNA
<213> D. melanogaster

<400> 62
auaaagcuag acaaccauug a 21

<210> 63

<211> 23
<212> RNA
<213> D. melanogaster

<400> 63
aaaggaacga ucguugugau aug 23

<210> 64
<211> 22
<212> RNA
<213> D. melanogaster

<400> 64
uaucaacagug gcuguucuuu uu 22

<210> 65
<211> 23
<212> RNA
<213> D. melanogaster

<400> 65
uggaagacua gugauuuugu ugu 23

<210> 66
<211> 23
<212> RNA
<213> D. melanogaster

<400> 66
uaauacuguc agguaaagau guc 23

<210> 67
<211> 23
<212> RNA
<213> D. melanogaster

<400> 67
ucuuugguua ucuagcugua uga 23

<210> 68
<211> 21
<212> RNA
<213> D. melanogaster

<400> 68
accuguguaga uccgaauuug u 21

<210> 69
<211> 21
<212> RNA
<213> D. melanogaster

<400> 69
caucacaguc ugaguucuug c 21

<210> 70
<211> 23
<212> RNA
<213> D. melanogaster

<400> 70
ugaguauuac aucagguacu ggu 23

<210> 71
<211> 22
<212> RNA
<213> D. melanogaster

<400> 71
uaucaacagcc auuuugacga gu 22

<210> 72
<211> 22
<212> RNA
<213> D. melanogaster

<400> 72
uaucaacagcc auuuugauga gu 22

<210> 73
<211> 21
<212> RNA
<213> D. melanogaster

<400> 73
ucagucuuuu ucucucuccu a 21

<210> 74
<211> 22
<212> RNA
<213> D. melanogaster

<400> 74
ugagguagua gguuguauag uu 22

<210> 75
<211> 22
<212> RNA
<213> Human

<400> 75
ugagguagua gguuguauag uu 22

<210> 76
<211> 22
<212> RNA
<213> Human

<400> 76
ugagguagua gguugugugg uu 22

<210> 77
<211> 22
<212> RNA
<213> Human

<400> 77
ugagguagua gguugaugg uu 22

<210> 78
<211> 21
<212> RNA
<213> Human

<400> 78
agagguagua gguugcauag u 21

<210> 79

<211> 21
<212> RNA
<213> Human

<400> 79
ugagguagga gguuguauag u 21

<210> 80
<211> 22
<212> RNA
<213> Human

<400> 80
ugagguagua gauuguauag uu 22

<210> 81
<211> 22
<212> RNA
<213> Human

<400> 81
uagcagcaca uaaugguuug ug 22

<210> 82
<211> 22
<212> RNA
<213> Human

<400> 82
uagcagcacg uaaaauuug cg 22

<210> 83
<211> 20
<212> RNA
<213> Human

<400> 83
acugcaguga aggcacuugu 20

<210> 84
<211> 22
<212> RNA
<213> Human

<400> 84

uaaggugcau cuagugcaga ua

22

<210> 85

<211> 23

<212> RNA

<213> Human

<400> 85

ugugcaaauc uaugcaaaac uga

23

<210> 86

<211> 23

<212> RNA

<213> Human

<400> 86

ugugcaaauc caugcaaaac uga

23

<210> 87

<211> 22

<212> RNA

<213> Human

<400> 87

uaaagugcuu auagugcagg ua

22

<210> 88

<211> 22

<212> RNA

<213> Human

<400> 88

uagcuuauca gacugauguu ga

22

<210> 89

<211> 22

<212> RNA

<213> Human

<400> 89

aagcugccag uugaagaacu gu

22

<210> 90
<211> 21
<212> RNA
<213> Human

<400> 90
aucacauugc cagggauuuc c

21

<210> 91
<211> 22
<212> RNA
<213> Human

<400> 91
uggcucaguu cagcaggaac ag

22

<210> 92
<211> 22
<212> RNA
<213> Human

<400> 92
cauugcacuu gucucggucu ga

22

<210> 93
<211> 22
<212> RNA
<213> Human

<400> 93
uucaaguaau ccaggauagg cu

22

<210> 94
<211> 22
<212> RNA
<213> Human

<400> 94
uucaaguaau ucaggauagg uu

22

<210> 95

<211> 22
<212> RNA
<213> Human

<400> 95
uucacagugg cuaaguuccg cu 22

<210> 96
<211> 22
<212> RNA
<213> Human

<400> 96
aaggagcuca cagucuauug ag 22

<210> 97
<211> 22
<212> RNA
<213> Human

<400> 97
cuagcaccau cugaaaucgg uu 22

<210> 98
<211> 22
<212> RNA
<213> Human

<400> 98
cuuucagucg gauguuugca gc 22

<210> 99
<211> 21
<212> RNA
<213> Human

<400> 99
ggcaagaugc uggcauagcu g 21

<210> 100
<211> 21
<212> RNA
<213> Human

<400> 100
uauugcacau uacuaaguug c 21

<210> 101
<211> 19
<212> RNA
<213> Human

<400> 101
gugcauugua guugcauug 19

<210> 102
<211> 22
<212> RNA
<213> Human

<400> 102
uggaauguaa agaaguaugg ag 22

<210> 103
<211> 23
<212> RNA
<213> Human

<400> 103
uggaagacua gugauuuugu ugu 23

<210> 104
<211> 23
<212> RNA
<213> Human

<400> 104
ucuuugguua ucuagcugua uga 23

<210> 105
<211> 21
<212> RNA
<213> Human

<400> 105
accuguaga uccgaauuug u 21

<210> 106
<211> 22
<212> RNA
<213> Mouse

<400> 106
ugagguagua gguuguauag uu

22

<210> 107
<211> 22
<212> RNA
<213> Mouse

<400> 107
ugagguagua gguugugugg uu

22

<210> 108
<211> 22
<212> RNA
<213> Mouse

<400> 108
ugagguagua gguuguaugg uu

22

<210> 109
<211> 21
<212> RNA
<213> Mouse

<400> 109
agagguagua gguugcauag u

21

<210> 110
<211> 21
<212> RNA
<213> Mouse

<400> 110
ugagguagga gguuguauag u

21

<210> 111

<211> 22
<212> RNA
<213> Mouse

<400> 111
ugagguagua gauuguauag uu 22

<210> 112
<211> 22
<212> RNA
<213> Mouse

<400> 112
ugagguagua guuuguacag ua 22

<210> 113
<211> 22
<212> RNA
<213> Mouse

<400> 113
ugagguagua guguguacag uu 22

<210> 114
<211> 19
<212> RNA
<213> Mouse

<400> 114
ugagguagua guuugugcu 19

<210> 115
<211> 22
<212> RNA
<213> Mouse

<400> 115
uggaauguaa agaaguaugu aa 22

<210> 116
<211> 22
<212> RNA
<213> Mouse

<400> 116
uggaauguaa agaaguaugu ac

22

<210> 117
<211> 23
<212> RNA
<213> Mouse

<400> 117
uggaauguaa agaaguaugu auu

23

<210> 118
<211> 23
<212> RNA
<213> Mouse

<400> 118
ucuuugguua ucuagcugua uga

23

<210> 119
<211> 22
<212> RNA
<213> Mouse

<400> 119
uagcagcaca uaaugguuug ug

22

<210> 120
<211> 22
<212> RNA
<213> Mouse

<400> 120
uagcagcaca ucaugguuua ca

22

<210> 121
<211> 22
<212> RNA
<213> Mouse

<400> 121
uagcagcacg uaaauauugg cg

22

<210> 122
<211> 22
<212> RNA
<213> Mouse

<400> 122
uaaggugcau cuagugcaga ua 22

<210> 123
<211> 23
<212> RNA
<213> Mouse

<400> 123
ugugcaaauc caugcaaaac uga 23

<210> 124
<211> 23
<212> RNA
<213> Mouse

<400> 124
uaaagugcuu auagugcagg uag 23

<210> 125
<211> 22
<212> RNA
<213> Mouse

<400> 125
uagcuuauca gacugauguu ga 22

<210> 126
<211> 22
<212> RNA
<213> Mouse

<400> 126
aagcugccag uugaagaacu gu 22

<210> 127

<211> 21
<212> RNA
<213> Mouse

<400> 127
aucacauugc cagggauuuc c 21

<210> 128
<211> 23
<212> RNA
<213> Mouse

<400> 128
aucacauugc cagggauuac cac 23

<210> 129
<211> 22
<212> RNA
<213> Mouse

<400> 129
uggcucaguu cagcaggaac ag 22

<210> 130
<211> 22
<212> RNA
<213> Mouse

<400> 130
uucaaguaau ccaggauagg cu 22

<210> 131
<211> 22
<212> RNA
<213> Mouse

<400> 131
uucaaguaau ucaggauagg uu 22

<210> 132
<211> 22
<212> RNA
<213> Mouse

<400> 132
uucacagugg cuaaguuccg cu 22

<210> 133
<211> 20
<212> RNA
<213> Mouse

<400> 133
uucacagugg cuaaguucug 20

<210> 134
<211> 22
<212> RNA
<213> Mouse

<400> 134
cuagcaccau cugaaaucgg uu 22

<210> 135
<211> 23
<212> RNA
<213> Mouse

<400> 135
uagcaccauu ugaaaucagu guu 23

<210> 136
<211> 22
<212> RNA
<213> Mouse

<400> 136
uagcaccauu ugaaaucggg ua 22

<210> 137
<211> 23
<212> RNA
<213> Mouse

<400> 137
uguaaacauc cugacugga agc 23

<210> 138
<211> 22
<212> RNA
<213> Mouse

<400> 138
cuuucagucg gauguuugca gc 22

<210> 139
<211> 21
<212> RNA
<213> Mouse

<400> 139
uguuaaacauc cuacacucag c 21

<210> 140
<211> 23
<212> RNA
<213> Mouse

<400> 140
uguuaaacauc cuacacucuc agc 23

<210> 141
<211> 22
<212> RNA
<213> Mouse

<400> 141
uguuaaacauc cccgacugga ag 22

<210> 142
<211> 20
<212> RNA
<213> Mouse

<400> 142
acccguagau ccgaucuugu 20

<210> 143

<211> 22
<212> RNA
<213> Mouse

<400> 143
caccgcguaga accgaccuug cg 22

<210> 144
<211> 20
<212> RNA
<213> Mouse

<400> 144
uacaguacug ugauaacuga 20

<210> 145
<211> 23
<212> RNA
<213> Mouse

<400> 145
uggaguguga caaugguguu ugu 23

<210> 146
<211> 23
<212> RNA
<213> Mouse

<400> 146
uggaguguga caaugguguu uga 23

<210> 147
<211> 22
<212> RNA
<213> Mouse

<400> 147
uggaguguga caaugguguu ug 22

<210> 148
<211> 21
<212> RNA
<213> Mouse

<400> 148
cauuauuacu uuugguacgc g

21

<210> 149
<211> 22
<212> RNA
<213> Mouse

<400> 149
uuaaggcacg cggugaaugc ca

22

<210> 150
<211> 21
<212> RNA
<213> Mouse

<400> 150
uuaaggcacg cgggugaaug c

21

<210> 151
<211> 23
<212> RNA
<213> Mouse

<400> 151
ucccugagac ccuuuaaccu gug

23

<210> 152
<211> 22
<212> RNA
<213> Mouse

<400> 152
ucccugagac ccuaacuugu ga

22

<210> 153
<211> 21
<212> RNA
<213> Mouse

<400> 153
ucguaccgug aguaauaauug c

21

<210> 154
<211> 22
<212> RNA
<213> Mouse

<400> 154
ucggauccgu cugagcuugg cu

22

<210> 155
<211> 22
<212> RNA
<213> Mouse

<400> 155
ucacagugaa ccggucucuu uu

22

<210> 156
<211> 21
<212> RNA
<213> Mouse

<400> 156
cuuuuuucgg ucugggcuug c

21

<210> 157
<211> 20
<212> RNA
<213> Mouse

<400> 157
cagugcaaug uaaaaagggc

20

<210> 158
<211> 21
<212> RNA
<213> Mouse

<400> 158
uaaagcuaga uaaccgaaag u

21

<210> 159

<211> 23
<212> RNA
<213> Mouse

<400> 159
uaacagucua cagccauggu cgu

23

<210> 160
<211> 22
<212> RNA
<213> Mouse

<400> 160
uugguucccu ucaaccagcu gu

22

<210> 161
<211> 22
<212> RNA
<213> Mouse

<400> 161
ugugacuggu ugaccagagg ga

22

<210> 162
<211> 24
<212> RNA
<213> Mouse

<400> 162
uauggcuuuu uauuccuaug ugaa

24

<210> 163
<211> 23
<212> RNA
<213> Mouse

<400> 163
acuccauuug uuuugaugau gga

23

<210> 164
<211> 22
<212> RNA
<213> Mouse

<400> 164
uauugcuuaa gaauacgcgu ag 22

<210> 165
<211> 17
<212> RNA
<213> Mouse

<400> 165
agcugguguu gugaau 17

<210> 166
<211> 18
<212> RNA
<213> Mouse

<400> 166
ucuacagugc acgugucu 18

<210> 167
<211> 21
<212> RNA
<213> Mouse

<400> 167
agugguuuaa ccuauaggua g 21

<210> 168
<211> 21
<212> RNA
<213> Mouse

<400> 168
aacacugucu gguaaagaug g 21

<210> 169
<211> 20
<212> RNA
<213> Mouse

<400> 169
cauaaaguag aaagcacuac 20

<210> 170
<211> 22
<212> RNA
<213> Mouse

<400> 170
uguaguguuu ccuacuuuau gg 22

<210> 171
<211> 22
<212> RNA
<213> Mouse

<400> 171
ugagaugaag cacuguagcu ca 22

<210> 172
<211> 22
<212> RNA
<213> Mouse

<400> 172
uacaguauag augauguacu ag 22

<210> 173
<211> 24
<212> RNA
<213> Mouse

<400> 173
guccaguuuu cccaggauc ccuu 24

<210> 174
<211> 23
<212> RNA
<213> Mouse

<400> 174
ugagaacuga auuccauggg uuu 23

<210> 175

<211> 21
<212> RNA
<213> Mouse

<400> 175
guguguggaa augcuucugc c 21

<210> 176
<211> 22
<212> RNA
<213> Mouse

<400> 176
ucagugcacu acagaacuuu gu 22

<210> 177
<211> 22
<212> RNA
<213> Mouse

<400> 177
ucuggcuccg ugucuucacu cc 22

<210> 178
<211> 23
<212> RNA
<213> Mouse

<400> 178
ucucccaacc cuuguaccag ugu 23

<210> 179
<211> 22
<212> RNA
<213> Mouse

<400> 179
cuagacugag gcuccuugag gu 22

<210> 180
<211> 21
<212> RNA
<213> Mouse

<400> 180
ucagugcaug acagaacuug g 21

<210> 181
<211> 20
<212> RNA
<213> Mouse

<400> 181
uugcauaguc acaaaaguga 20

<210> 182
<211> 22
<212> RNA
<213> Mouse

<400> 182
uagguuaucc guguugccuu cg 22

<210> 183
<211> 22
<212> RNA
<213> Mouse

<400> 183
uuaaugcuaa uugugauagg gg 22

<210> 184
<211> 23
<212> RNA
<213> Human/Mouse

<400> 184
aacaaucaac gcugucggug agu 23

<210> 185
<211> 22
<212> RNA
<213> Human/Mouse

<400> 185
uuuggcaaug guagaacuca ca 22

<210> 186
<211> 23
<212> RNA
<213> Human/Mouse

<400> 186
uauggcacug guagaaauca cug

23

<210> 187
<211> 22
<212> RNA
<213> Human/Mouse

<400> 187
cuuuuugcgg ucugggcug uu

22

<210> 188
<211> 22
<212> RNA
<213> Human/Mouse

<400> 188
uggacggaga acugauaagg gu

22

<210> 189
<211> 18
<212> RNA
<213> Human/Mouse

<400> 189
uggagagaaa ggcaguuc

18

<210> 190
<211> 23
<212> RNA
<213> Human/Mouse

<400> 190
caaagaauuc uccuuuuggg cuu

23

<210> 191

<211> 22

<212> RNA

<213> Human/Mouse

<400> 191

ucgugucuug uguugcagcc gg

22

<210> 192

<211> 21

<212> RNA

<213> Human/Mouse

<400> 192

uaacacuguc ugguaacgau g

21

<210> 193

<211> 22

<212> RNA

<213> Human/Mouse

<400> 193

caucccuugc augguggagg gu

22

<210> 194

<211> 23

<212> RNA

<213> Human/Mouse

<400> 194

gugccuacug agcugacauc agu

23

<210> 195

<211> 22

<212> RNA

<213> Human/Mouse

<400> 195

ugauauguuu gauauuuag gu

22

<210> 196

<211> 22

<212> RNA

<213> Human/Mouse

<400> 196
caacggaauc ccaaaagcag cu 22

<210> 197
<211> 18
<212> RNA
<213> Human/Mouse

<400> 197
cugaccuaug aaugaca 18

<210> 198
<211> 22
<212> RNA
<213> Human/Mouse

<400> 198
uaccacaggg uagaaccacg ga 22

<210> 199
<211> 21
<212> RNA
<213> Human/Mouse

<400> 199
aacuggccua caaagucca g 21

<210> 200
<211> 22
<212> RNA
<213> Human/Mouse

<400> 200
uguaacagca acuccaugug ga 22

<210> 201
<211> 21
<212> RNA
<213> Human/Mouse

<400> 201
uagcagcaca gaaauuugg c 21

<210> 202

<211> 21

<212> RNA

<213> Human/Mouse

<400> 202

uagguaguuu cauguuguug g

21

<210> 203

<211> 22

<212> RNA

<213> Human/Mouse

<400> 203

uucaccaccu ucuccaccca gc

22

<210> 204

<211> 19

<212> RNA

<213> Human/Mouse

<400> 204

gguccagagg ggagauagg

19

<210> 205

<211> 22

<212> RNA

<213> Human/Mouse

<400> 205

cccaguguuc agacuaccug uu

22

<210> 206

<211> 23

<212> RNA

<213> Human/Mouse

<400> 206

uaauacugcc ugguaaugau gac

23

<210> 207

<211> 21
<212> RNA
<213> Human/Mouse

<400> 207
uacucaguaa ggcauguuuc u 21

<210> 208
<211> 22
<212> RNA
<213> Human/Mouse

<400> 208
agagguauag cgcaugggaa ga 22

<210> 209
<211> 21
<212> RNA
<213> Human/Mouse

<400> 209
ugaaauguuu aggaccacua g 21

<210> 210
<211> 23
<212> RNA
<213> Human/Mouse

<400> 210
uucccuuugu cauccuauuc cug 23

<210> 211
<211> 22
<212> RNA
<213> Human/Mouse

<400> 211
uccuucuuuc caccggaguc ug 22

<210> 212
<211> 23
<212> RNA
<213> Human/Mouse

<400> 212
gugaaauguu uaggaccacu aga

23

<210> 213
<211> 22
<212> RNA
<213> Human/Mouse

<400> 213
uggaauguaa ggaagugugu gg

22

<210> 214
<211> 22
<212> RNA
<213> Human/Mouse

<400> 214
uacaguaguc ugcacauugg uu

22

<210> 215
<211> 22
<212> RNA
<213> Human/Mouse

<400> 215
cccuguagaa ccgaauuugu gu

22

<210> 216
<211> 24
<212> RNA
<213> Human/Mouse

<400> 216
aaccguaga uccgaacuug uga

24

<210> 217
<211> 23
<212> RNA
<213> Human/Mouse

<400> 217
gcuucuccug gcucuccucc cuc

23